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ABSTRACT
DEVELOPMENT OF CHROMATOGRAPHY AND MASS SPECTROMETRY METHODS
FOR ENZYME KINETICS AND INHIBITION IN GLYCOLYSIS AND THE
METHYLERYTHRITOL PHOSPHATE (MEP) PATHWAYS

Allison Fabino Carr, Ph.D.
Department of Chemistry and Biochemistry
Northern Illinois University, 2019
Victor Ryzhov, Director

This dissertation focuses on method development for enzymatic activity and inhibition
assays for use in screening potential antibacterial compounds. Infection by antibiotic-resistant
pathogens in on the rise globally and several enzymes, including the those in the methylerythritol
phosphate (MEP) pathway and fructose bisphosphate aldolase, as strong targets for novel
pharmaceuticals because they are not present in humans. Several assays exist for the MEP pathway
and aldolase, but there is always work to be done to improve sensitivity, increase throughput, and
lower cost. This dissertation describes the development of several methods – hydrophilic
interaction chromatography (HILIC), liquid chromatography-mass spectrometry (LC-MS), and
high resolution-mass spectrometry (HR-MS) – to detect and quantitative enzymatically-relevant
analytes. The HILIC method was used to identify nucleotide analytes from the MEP pathway and
was applied to LC-MS with no post-column desalting. In addition, the procedure was transferred
for the analysis of fructose bisphosphate (FBP), the substrate of the aldolase reaction, with no
changes. Additionally, an HR-MS was developed and validated to detect and quantitate FBP with
high specificity and precision. Furthermore, the validated HR-MS method was used to obtain
kinetic data from rabbit muscle aldolase uninhibited and with known inhibitors adenosine

monophosphate (AMP) and adenosine triphosphate (ATP). Results confirmed that the HR-MS
method was able to detect and quantitate enzyme turnover in quenched aliquots of reaction
mixture. Future work will focus on using HR-MS detection to continuously monitor reactions in
situ in order to save time, labor, and cost. Finally, the goal is to combine the HILIC method with
the continuous HR-MS method to study kinetics and inhibition of a variety of target enzymes
against libraries of potential inhibitors in vitro and in vivo.
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CHAPTER 1
INTRODUCTION

A Brief History of Antibiotics

Antibiotics have been used by humanity since ancient times.1 Perhaps the most well-known
and widely-successful antibiotics in history is penicillin, which was serendipitously discovered in
1928 by Alexander Fleming. Years after the initial discovery, Ernst Chain and Howard Florey
were able to purify and mass-produce penicillin, helping it to become “the wonder drug” that saved
countless lives during World War II.2 In the decades since the end of World War II, penicillin and
its derivatives – including amoxicillin, ampicillin, and methicillin – have continued to be used.
Additionally, other antibiotic classes against several targets have been developed such as
cephalosporins, fluoroquinolones, sulfonamides, and tetracyclines. However, in recent decades
antibiotic development has slowed significantly and only two new classes have made it to market
since the mid-1960s.3

The Emerging Threat of Antibiotic-Resistant Pathogens

When Alexander Fleming discovered penicillin, he also predicted that there would come a
time in the future when it would no longer be an effective treatment due to bacterial resistance.4
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Bacterial antibiotic resistance is an unfortunate effect of natural selection and the theory of
evolution.5 As bacteria reproduce extremely quickly, mutations that induce resistance can form
and be passed on to future generations within a short timeframe from initial antibiotic treatment.45

Overuse in both humans and livestock, misuse, and the recent plateau in new antibiotic

development1a, 6 have led both the US Centers for Disease Control and Prevention (CDC) and
World Health Organization (WHO) to declare antibiotic resistant pathogens as a serious global
threat.7 Examples of antibiotic resistant pathogens are seen in the figure below and include:
MRSA/VRSA, MDR/XDR tuberculosis, and malaria.
New Targets for Antibacterial Drugs

Although the pathogens described above represent the biggest threats to humanity and
work on pathogen-specific antibiotics is underway, the true future of antibiotics lies in creating
broad-spectrum drugs designed to treat a wide array of infections.8 These new drugs should display
several desirable characteristics including being effective at low doses (high potency) with few
debilitating side effects (low toxicity).9 The best way to ensure a low occurrence of off-target
effects is to choose a bacterial target (such as an enzyme or receptor) that is not present in
humans.10 The targets described below are very promising because of their necessity for bacterial
survival, and the idea that a compound could be designed that has a specificity for the target and
limited toxicity of the host organism.

3

Figure 1.1:
A timeline produced by the US Centers for Disease Control and Prevention (CDC)
highlighting the issue of antibiotic resistance by a showing the year an antibiotic is introduced
(right) compared to the first known instance of resistance (left).11
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One long-studied antibacterial target that is not present in humans is the enzymes involved
in cell wall biosynthesis. The primary product of this series of enzymes is peptidoglycan, and
because human cells have membranes but not walls, it is not essential for the viability of human
cells.12 On the other hand, bacterial cells have cell walls and peptidoglycan is vital to cell
survival.13 This difference in humans and bacteria has been used to great effect with β-lactam
antibiotics – e.g. penicillins and cephalosporins – which inhibit the group of proteins that crosslink peptidoglycan, aptly named penicillin-binding proteins (PBPs), into cell walls.13-14 However,
bacteria have developed mechanisms to deactivate β-lactams (namely β-lactamase enzymes) and
novel antibiotics are constantly needed to keep up with resistance.13, 15 Another high priority target
for antibiotic development is enzymes involved in energy metabolism. Energy production and
metabolism are vital for cell survival and many of these enzymes are either not present in humans
or display a different catalytic mechanism and/or active site structure than the human versions,
including but not limited to: fructose bisphosphate aldolase, acetate kinase, phosphotransacetylase,
formate acetyltransferase, and xylitol dehydrogenase.15 The specific targets discussed below each
represent one of the classic antibacterial targets absent in humans: the methylerythritol phosphate
pathway, which aids in isoprenoid synthesis for cell membranes and fructose bisphosphate
aldolase, an essential glycolysis enzyme.
The Methylerythritol Phosphate (MEP) Pathway

The methyl erythritol phosphate (MEP) pathway is essential for the survival of bacterial
gram-negative and some gram-positive species, making it an attractive target for novel antibiotics
to treat drug-resistant infections.16 The MEP pathway involves a series of seven enzymes that
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produce the isoprenoid precursors IPP and DMAPP.17 All MEP pathway enzymes can be
inhibited16a but based on previous research on the MEP pathway, the first five enzymes in the
pathway – DXS, DXR, IspD, IspE, and IspF – are the strongest targets for future drug
development.18 The isoprenoids produced from the precursors are essential for cellular
membranes, steroid production, and ubiquinone synthesis for use in cellular respiration.17b,

19

Therefore, inhibitors of MEP pathway enzymes are bactericidal.16b Animals also biosynthesize IPP
and DMAPP, but they do so via the mevalonate pathway, which does not have any enzymes in
common with the MEP pathway.19-20 This is the main reason the MEP pathway is such a popular
target for antibiotic development.17b, 21 The goal is to develop drugs that would be very effective
against bacterial infections, with little effect against human cells.9

Figure 1.2:
and IspF.

Example reactions of frequently studied enzymes in the MEP pathway: IspD, IspE,
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As there is a lot of interest in the MEP pathway, many methods exist to evaluate inhibition
of MEP pathway enzymes. These methods represent a variety of different platforms, sensitivities,
and throughputs. Plate-based assays are commonly used, most of which are coupled-enzyme
assays. One such example is the Kinase Glo assay, which quantifies kinase activity based on the
decrease in ATP concentration.22 The Kinase Glo assay can be used to study IspE activity.23 The
kinase reaction will convert ATP to ADP until the reaction reaches equilibrium, and any leftover
ATP will be used in the enzymatic conversion of luciferin to oxyluciferin by the enzyme
luciferase.22b, 24 The luciferase-catalyzed reaction releases a photon and the chemiluminescent
signal can be read on a plate reader.24 Luminescent signal is inversely proportional to ATP
concentration and the ATP concentration can be stoichiometrically related to product formation to
yield enzymatic reaction rates.23 Kinase Glo assay kits are commercially sold and most of the
experimental conditions are optimized.

Figure 1.3:
Illustrated reaction schemes showing the basis of the Kinase-Glo assay, sold by
Promega Corporation.25
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For the IspD-catalyzed reaction, phosphate ions released as product can be quantified by
the EnzChek phosphate assay kit.26 The assay relies on coupled enzyme reactions, in which the
inorganic phosphate released by the IspD reaction is used alongside 2-amino-6-mercapto-7methylpurine riboside (MESG) as the substrates of purine nucleoside phosphorylase (PNP). One
of the products formed by this reaction, 2-amino-6-mercapto-7-methylpurine, absorbs at 360 nm
and by monitoring the absorbance over time on a plate reader, the absorbance can be directly
related to the amount of IspD activity.26

Figure 1.4:

Reaction scheme of the EnzChek phosphate assay.27
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Another example of a plate-based assay uses fluorescence detection to quantitate IspF
activity.28 In this scheme, the CMP produced as a by-product of the IspF reaction is combined with
ATP and nucleotide monophosphate kinase (NMK) to produce ADP. That ADP is used in the
pyruvate kinase reaction to produce pyruvate. Pyruvate oxidase is then used to produce hydrogen
peroxide, which is used as an electron donor to convert Amplex-Red to resorufin horseradish
peroxidase. This oxidation reaction can be monitored by fluorescence with an excitation
wavelength of 530 nm and an emission wavelength of 590 nm. This is another indirect assay, with
signal from resorufin being directly proportional to the amount of CMP produced by the IspF
reaction.28 The plate-based format makes these assays high-throughput, and chemiluminescence
and fluorescence are very sensitive forms of detection. Also available in plate format is an assay
that follows the UV signal from the depletion of NADH. However, these assays are indirect,
involves multiple enzymatic steps, sometimes requiring special detectors or expensive assay kits.
A more direct assay for IspE utilizes TLC separation with radiometric detection.28 For this
assay, the reaction is run in vitro with all of the typical reagents but using γ-32P-labelled ATP. The
IspE kinase reaction converts ATP to ADP, TLC separates compounds from the reaction mixture,
and labelled ATP is detected with a phosphoimager. A decrease in ATP signal indicates that the
IspE reaction is proceeding forward.28 This assay can be quantitative and be used to determine
reaction rates. It is also very specific, with very low background signal and artifacts, extremely
sensitive, and relatively quick. The main issue with this assay is expense: it requires a radiolabelled substrate, the cost of which can add up over a series of runs.
Other MEP pathway assays utilize more widely-used techniques, like high performance
liquid chromatography (HPLC) or liquid chromatography-mass spectrometry (LC-MS). Anion
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exchange HPLC is a common choice for phosphate-containing analytes. IspD-binding compound
CDP-ribitol can be assayed using strong anion exchange HPLC in gradient elution mode and
quantitated by measuring absorbance at 280 nm.29 Similarly, IspF inhibition can be assayed with
an isocratic strong anion exchange method.30 In both cases, UV absorbance is used as a means of
determining concentrations and reaction rates. However, UV detection has fairly low sensitivity
and a more sensitive detection method such as mass spectrometry is needed for very dilute samples.
Unfortunately, neither method is ESI-MS-applicable because of high non-volatile salt
concentrations in the mobile phase: 0.05-0.5 M ammonium phosphate29 and 0.5 M sodium
phosphate30, respectively. Another HPLC technique that is commonly used is reversed-phase (RP)
combined with an ion-pairing (IP) reagent in the mobile phase. Since reversed-phase columns are
nonpolar and MEP pathway compounds contain polar phosphate groups, retention necessitates the
use of between 5-500 mM ion-pairing reagent, often in a shallow gradient of increasing
concentration of organic solvent. IspF reaction mixtures have been analyzed in this way using a
short “rocket” column running at a high flow rate.31 Reaction products CMP and CDPME2P were
well separated in a short gradient. In this case, 5 mM tetrabutyl ammonium bisulfate in phosphate
buffer was used as the ion-pairing reagent; and that, in addition to the 0.1% SDS quenching
reagent, made ESI-MS non-viable, thereby limiting the sensitivity of the method. Other IP reagents
are more applicable for ESI-MS, such as tributylamine which can be interfaced with ESI-MS at
low-millimolar concentrations.32

10

Fructose Bisphosphate Aldolase

Another potentially interesting target for antibiotic development is fructose bisphosphate
aldolase, or simply aldolase, which is part of two of the most critical enzymatic pathways in all of
biology: glycolysis and gluconeogenesis. Nearly complete opposites of each other, glycolysis is
the pathway that processes glucose to form free energy and pyruvate for the Krebs cycle, and
gluconeogenesis synthesizes glucose using energy and pyruvate.33 Both are integral to cellular
metabolism, energy production, and respiration so it is easy to see their value as “druggable”
enzymatic pathways.33a, 34 Aldolase catalyzes the reversible cleavage of fructose bisphosphate
(FBP) into dihydroxyacetone phosphate (DHAP) and glycerol 3-phosphate (G3P), an aldol
cleavage/condensation step.35 Depending on the type of organism, aldolase comes in two forms:
class I and class II.36 The mechanism of action for class I aldolases involves a Schiff-base
intermediate to link a lysine residue in the active site to the carbonyl group on dihydroxyacetone
phosphate.34, 37 This type of aldolase is found in plants and animals. On the other hand, bacteria
use class II aldolases, which have a totally different mechanism of action and little sequence
homogeny to the active site of class I aldolases.33a, 35a Class II aldolases are metalloenzymes,
which use a Zn2+ to bind to and polarize the carbonyl group on DHAP.33b, 35b, 38 Due to the
difference in active site structure and the extreme importance of the enzyme, aldolase is a very
promising target for future antibiotic development.
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Figure 1.5:
Reaction scheme of the reversible aldolase-catalyzed cleavage of fructose
bisphosphate.

The major assays that currently exist to study aldolase activity are colorimetric or
fluorometric coupled-enzyme assays following the reduction of NADH (which absorbs light at
340 nm) to NAD+ (which can be coupled to a fluorescence reaction). Therefore, colorimetric
assays will measure the decrease in A340 and fluorometric assays will measure the decrease in
signal from the excitation-emission (usually in the 520-590 nm range). The colorimetric assay is
more commonly used, but fluorescence provides a much higher sensitivity, albeit at higher cost
because of the necessity of a fluorophore. Although these assays are extremely sensitive, they are
plate-based and require expensive and material-heavy kits to be purchased, lowering the
throughput of the assay. As many labs already contain the required instrumentation, HPLC and
LC-MS assays offer cost savings and can run continuously with little user input. In addition, LCMS can directly analyze compounds in the aldolase reaction, instead of requiring coupled enzyme
reactions and stoichiometrically relating signal from NADH to aldolase products. This direct
method also requires less incubation time and sample preparation, saving time, effort, cost, and
materials while reducing matrix effect.
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Figure 1.6:
activity. 39

Illustrated procedure for the multi-step Elite Kit fluorometric assay for aldolase
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Reaction scheme for the coupled-enzyme colorimetric assay for aldolase activity.

13

Aim of This Work

The aim of this work is to develop LC, MS, and LC-MS methods able to quantitate enzyme activity
and inhibition and offering significant improvements in throughput, sensitivity, cost, and material
use compared to traditional plate-based, coupled-enzyme, and spectrophotometric assays.
Additionally, the methods will also provide direct analysis of reaction biomarkers in vivo. This
allows for confirmation that an inhibitor is acting on the enzyme of interest and not an off-target
site. This information is pertinent when developing drugs because it ensures specificity. Ideally,
the protocols developed here could be used for various enzymes and pathways with only minor
changes. The long-term goal of this work is to use the data obtained to describe the potency and
specificity of enzyme inhibitors for use as potential antimicrobial drugs, which are desperately
needed in the age of antibiotic-resistant pathogens.
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CHAPTER 2
METHODS

High Performance Liquid Chromatography (HPLC)

High performance liquid chromatography has been used for decades as a robust and highthroughput method to separate and quantitate analytes in the liquid phase. The basis of the
separation power lies in the extrapolation of property (usually polarity) differences between
compounds in a mixture and involves two phases: the stationary phase (an immobile solid phase,
usually a packed column) and mobile phase (a solvent which carries the sample through the
stationary phase). Similar to a liquid-liquid extraction, separation occurs based on partitioning of
compounds between the two phases. Since the stationary and mobile phases have different
polarities themselves, compounds will differentially partition toward one phase or another, and
over time this will lead to their separation. Depending on the type of analyte, stationary/mobile
phase properties, column length, temperature, mobile phase flow, etc. can all be fine-tuned.
Therefore, HPLC is considered one of the most useful and widely applicable techniques in
analytical chemistry.
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Hydrophilic Interaction Liquid Chromatography (HILIC)

Since its development in 1990, hydrophilic interaction, or HILIC, chromatography has
revolutionized the analysis of polar and ionizable compounds.40 HILIC combines a polar stationary
phase (as in normal phase chromatography) that often contains ionizable groups (as in ion
chromatography)

with

the

water-acetonitrile

mobile

phase

used

in

reversed-phase

chromatography. The retention mechanism in HILIC chromatography is two-fold. As the name
implies, the primary retention mechanism is based on the interactions between the hydrophilic
stationary phase and analyte. This can be due to dipole-dipole, charge-dipole or charge-charge
interactions. In addition to hydrophilic interactions, there is also partitioning of the analyte within
the water-rich layer of the mobile phase around the stationary phase particles and the organic-rich
layer. Different stationary phases provide varying degrees of hydrophilic interaction vs.
partitioning mechanisms depending on their polarity and the number of ionizable groups present.4041

At present, a variety of HILIC stationary phases are commercially available, the most
common of which is bare silica. At near-neutral pH, silica can act as a cation exchanger because
of the formation of deprotonated silanol groups; however, the specificity is limited to more basic
analytes and retention of acidic analytes is poor. Also widely used are neutral bonded phases, such
as hydroxyl- and amido-bonded silica. Hydroxyl phases show almost no ion-exchange activity and
retention of polar analytes is predominately due to partitioning. On the other hand, amide phases
exhibit a high degree of hydrogen-bonding to analytes while also creating strong water-acetonitrile
partitioning. Therefore, amide columns are applicable for a variety of neutral and charged analytes.
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Figure 2.1:
A visual representation of the overlap between HILIC chromatography and ionexchange (IEX), reversed-phase (RPLC), and normal-phase (NPLC). 42

Zwitterionic (charged, but net neutral) stationary phases exhibit very high overall retention and are
also effective at separating neutral and charged analytes. Despite the presence of charged groups
on the stationary phase, ion-exchange is not the principal retention mechanism. Instead, the
extremely high stationary phase hydrophilicity promotes analyte partitioning within the mobile
phase. For anion-exchange of acidic analytes, there are also amino stationary phases which can be
protonated.41 Furthermore, the above only represent the most commonly used HILIC stationary
phases, and a variety of other commercial and proprietary phases exist for more narrow application.
With such a large number of HILIC stationary phases available, great care must be taken
when selecting a stationary phase for a particular application or analyte. In addition, several mobile
phase factors such as %ACN and pH also play vital roles in determining the ionization state of
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both the stationary phase and analyte and the degree of partitioning. A generic mobile phase used
for HILIC is a combination of a large fraction of acetonitrile and a small fraction of water (but no
smaller than 5% (v/v) to ensure some partitioning). In practice, the solution is often buffered to
control pH, as the analyte and/or stationary phase may contain pH-dependent ionizable groups.
HILIC runs can either be isocratic or gradient, and column equilibration times are at least 20
column volumes. Because of the long equilibration times, isocratic elution is preferable for fast
analysis. On the other hand, the multi-faceted retention mechanism increases molecular drag and
causes peaks to tail in most HILIC methods. In this case, using a gradient or incorporating coreshell technology into particles can improve the peak shape.41b
As the majority of the analytes of interest in this work are contain phosphate moieties,
HILIC is the ideal separation choice for LC and LC-MS. Chapter 3 focuses on HPLC method
development and the comparison of HILIC to other separation techniques for phosphate analytes:
strong anion exchange (SAX) HPLC and ion-pair reversed-phase (IP-RP). In this chapter, the
advantages and disadvantages of each of these three techniques are evaluated. In addition, method
development and comparative analyses are shown for five nucleotide analytes in the MEP
pathway.

Drawbacks of HPLC Alone

Liquid chromatography analysis is applicable to complex matrices and can separate (based
on stationary phase) and detect (based on detector) analytes with various properties. Many
researchers utilize LC, and since it is the most popular analytical technique worldwide, there are
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lots of resources for method development across different applications. However, HPLC is not
applicable to every analyte in every instance. The biggest disadvantage of HPLC is the limited
number of detectors available commercially. In order of increasing specificity, the most typical
detectors are refractive index (RI), evaporative light scattering (ELS), UV or UV-Vis, and
fluorescence. Depending on the number of analytes and their respective absorption properties,
these four detectors may not provide the requisite specificity or selectivity needed for quantitative
analysis. In that case, HPLC can be interfaced with other detection techniques.
For the nucleotides and sugar-phosphates of interest in this work, the typical HPLC
detectors are applied with mixed success. For complex matrices such as biological samples, RI
and ELS are generally negated due to their low specificity. Many of the compounds of interest for
the MEP pathway, namely nucleotides, have aromatic, UV-active DNA bases (e.g. cytosine and
adenine) that absorb UV at 272 and 260 nm, respectively. However, MEP pathway compounds
that do not contain these functional groups are excluded from detection because they lack any
chromophore. This is also the case with fructose bisphosphate, dihydroxyacetone phosphate, and
glyceraldehyde 3-phosphate of the aldolase-catalyzed reaction. Because the ultimate aim of this
work is to develop enzymatic assays that can be applied to multiple pathways with little-to-no
changes, UV is not the optimum detector because it only applies to a fraction of the compounds
on interest. Fluorescence detection has the same issue; none of the analytes in the MEP pathway
or the aldolase reaction naturally fluoresces.
Although UV and/or fluorescence detection may not work for many phosphate-containing
compounds in their native state, significant effort has been done to derivatize them to possess a
chromophore or fluorophore. For example, inositol phosphates, a group of biologically-relevant
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sugar phosphates lacking a chromophore for UV detection, have been derivatized post-column
with iron (III) nitrate for detection at 290 nm.43 Amino- and hydroxyl-groups on phospholipids
can be derivatized with chromophores or fluorophores.44 One example is derivatization of aminophospholipids with either 1-dimethylaminonaphthalene-5-sulfonyl (DNS) or succinimidyl 2naphthoxyacetate groups to enable fluorescence detection.44 Also, the thiamine group in thiaminecontaining nucleotides can be oxidized to form thiochrome fluorophore, significantly increasing
sensitivity compared to UV detection.45 For these and other derivatization methods to be viable,
the reaction needs to be relatively fast and high-yielding, leaving huge barriers to becoming a
routinely-used detection scheme.44 Therefore, direct analyte analyses are highly preferred
compared to derivatization.

Liquid Chromatography-Mass Spectrometry (LC-MS)

The interface of liquid chromatography and mass spectrometry is an extremely powerful
tool for qualitative and quantitative analysis. In this setup, a mass spectrometer is used either in
place of or in tandem with a typical UV detector. Mass spectrometers separate analytes based on
their mass-to-charge ratio (m/z) and are much more sensitive than UV detectors. In addition, MS
is a highly selective detector which can detect analytes that do not absorb in the UV range based
on their mass-to-charge, eliminating the need for analyte modification. Finally, MS provides an
extra degree of separation to LC, and is able to separate coeluting LC species as long as they have
different m/z values. This is especially helpful because it allows for the use of isotopically-labelled
internal standards, which would coelute in LC but be separated in MS.46
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There are several MS detection protocols that are commonly paired with chromatography.
The fastest and most basic detection scheme looks for certain ions in the mixture and refers them
to LC peaks. When one or more ion of interest is selected for screening and the other ions are
filtered out, it is called selected ion monitoring (SIM). To obtain an even greater level of
identification and sensitivity than single-stage MS, a technique called tandem mass spectrometry
(MS/MS) - which collects fragmentation data for a selected ion - can be performed. Fragmentation
is often induced by collision-induced dissociation (CID), in which the analyte of interest is
fragmented via collisions with a neutral gas such as He, N2, or Ar. The user inputs an energy value
added to the collision gas that determines the strength of collisions, which can lead to a variety of
fragmentation patterns in the analyte. Tandem mass spectrometry is especially important in
complex samples where more than one ion may have the same mass-to-charge ratio. These isobaric
ions would not be separated in single-stage MS, but MS/MS fragmentation data can elucidate them
using structure-based fragmentation patterns. For quantitation experiments, selected reaction
monitoring (SRM) is extremely common. One MS/MS ion pair is used for detection purposes (the
qualifier) and another is used for quantitation (the quantifier, usually the highest intensity peak).
These ion pairs are assigned based on their relative abundance is the spectra and the quantitation
limits of the system.46 When more than one pair of ions are being detected simultaneously, the
process is called multiple reaction monitoring (MRM).46
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Figure 2.2:
Example of selected ion monitoring and selected reaction monitoring of a dipeptide
using triple quadrupole mass spectrometry.

A variety of mass spectrometers can be used as part of an LC-MS system, but there are a
few that are more popular than others. These include the single quadrupole (Q), triple quadrupole
(QqQ), and hybrid instruments such as the quadrupole time-of-flight (QqTOF) or the linear iontrap combined with the Orbitrap (LIT-Orbitrap). For fast separation of ions less than 1000 Da,
single quadrupole instruments are used in conjunction with an LC system. The quadrupole mass
filter is able to screen out unwanted m/z values, either by selecting a mass range to get a full
spectrum (scanning mode) or a single m/z for selected ion monitoring (filtering mode). Q-MS
detectors are effective for general use and screening experiments but are not able to provide
MS/MS fragmentation data to distinguish isobaric ions. Therefore, for applications requiring
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identification of very low concentrations of analytes in complex sample matrices, single
quadrupole detectors may not provide sufficient sensitivity and/or selectivity.46
By far the most popular system used in LC-MS is the triple quadrupole or QqQ.
Designated the “workhorse instrument,” labs across all disciplines use triple quadrupole MS for
validation and quantitation of small molecules. Like the name suggests, a triple quadrupole
instrument is made up of three quadrupoles: Q1 and Q3 act as mass filters and q2 acts as a collision
cell for MS/MS fragmentation. Like with single quadrupole MS, ions can be detected in selected
ion monitoring mode by allowing passage through Q1 and q2, and operating Q3 in filtering mode
for the DC and RF voltages corresponding to the m/z of interest. However, this does not give
optimum performance or sensitivity. Instead, most QqQ methods will either be selected reaction
monitoring or multiple reaction monitoring. In both cases, Q1 will be used to filter out all ions
except a selected precursor ion, and from there the precursor will travel to q2 and undergo
fragmentation by collision induced dissociation with a neutral gas. This filtration process plays an
important role in increasing sensitivity. With a narrower range of masses travelling through the
system, the scan time is decreased, and thus more scans can be collected per unit time. Finally, all
fragment ions enter Q3 where all but a specified product ion are filtered out. Methods monitoring
a single ion pair are SRM, and MRM for multiple pairs. Reaction monitoring schemes are
extremely valuable for identifying analytes in complex sample matrices because selectivity is very
high, and background signal is diminished or eliminated by mass filtering leading to higher signal
to noise (S/N). Both of these contribute to the high sensitivity and low limits of quantitation (LOQ)
that make the triple quadrupole such a popular instrument.46
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When high mass accuracy is needed alongside sensitivity and MS/MS, a high-resolution
mass spectrometer can be coupled to LC. One example is a quadrupole time-of-flight (QqTOF),
which is set up like the triple quadrupole except that Q3 is a TOF detector. The time-of-flight mass
spectrometer applies a voltage along the flight tube (usually about 3 m long) whereby ions of
different masses and charge states will separate and arrive at the detector at different times. The
newest innovation in mass spectrometry technology is the Orbitrap, an ion-trap instrument in
which the ions orbit around a central spindle-shaped electrode and are separated based on the
different rotational frequencies caused by their m/z values in relation to the electric field strength.
Orbitrap mass analyzers do not exist as standalone instruments and are combined usually with
either a linear ion trap (LIT) or a quadrupole.46
Despite being the most widely used analytical technique, LC-MS presents a number of
challenges for method developers and analysts to overcome. Most LC-MS systems use
electrospray ionization (ESI) to get analytes into the gas phase. While ESI is extremely popular
and effective, maintaining appropriate ionization efficiency requires some method development of
LC mobile phase conditions. Spray efficiency is inversely related to flow rate in ESI-MS, but to
accommodate high LC flow rates parameters such as desolvation gas flow, auxiliary gas flow, and
spray temperature can be raised with limited positive results. Most modern ESI systems limit LC
flow rate to 1 mL/min, but many chromatography columns meant for LC-MS will run at lower
flow rates such as 0.2-0.8 mL/min. Choosing columns with smaller internal diameters to reduce
flow rates or introducing splitters into the post-column tubing can help with this issue without the
need for extensive MS tuning.47
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Another important consideration for ESI-MS is additives in the mobile phase. Electrospray
relies on gas- and temperature-based desolvation to get ions into the gas phase and is very sensitive
to non-volatile species.48 For example, buffer salts such as Tris, sulfates, and phosphates, as well
as IA and IIA salts (Na or Mg salts for example) will coat the spray source with crystals and
eventually completely obstruct flow into the mass spectrometer. Therefore, these salts should be
avoided, or the mobile phase should be desalted prior to entering the electrospray source. Also,
many mobile phases contain charged additives that can act as ion-pairing reagents or interfering
ions. A common example is sodium dodecyl sulfate (SDS), a detergent commonly found in
biological samples. SDS readily ionizes and presents as a very strong peak at m/z 265 in the
negative ion mode. This could be problematic, especially if there is an analyte of interest with m/z
at or near that value. Residual sodium (either from glassware or solutions) will be ionized (m/z 23)
and can pair with negatively-charged analytes, leaving a net zero charge and losing MS visibility.
The same is true of acidic additives like acetic acid or formic acid and their ability to bind to
positively-charged analytes. On the other hand, mobile phase additives in small concentrations can
be extremely useful if the analyte(s) of interest are not readily ionizable, which may not be seen in
mass spectrometry otherwise.47

High Resolution Mass Spectrometry (HR-MS) for Quantitation

Although MS is often combined with another separation technique (most often LC), it is
very valuable as a standalone technique. Mass spectrometry is very sensitive, requiring very little
material and significantly reducing experiment cost. It is also very fast, with total analysis times
in seconds or minutes. Any mass spectrometer is capable of obtaining quantitative data, but some
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instruments are better for sensitivity, structural elucidation, mass accuracy, etc. High resolution
mass spectrometry (HR-MS) gives high mass accuracy, such that the exact masses of compounds
are measured and those with the same nominal masses are separated.49 In general, high-resolution
mass spectrometers measure m/z to 0.001 mass units and a mass accuracy of 1-2 ppm.49b, 50 From
the exact masses, HR-MS can give chemical formulas for unknown analytes,51 and structural
information when MS/MS fragmentation is obtained. Time-of-flight (TOF), Orbitrap, and Fourier
transform-ion cyclotron resonance (FT-ICR) instruments are all high resolution – with resolving
powers of 60000, 240000, and 1000000, respectively52 - and can be hybridized with quadrupoles
in order to be MS/MS-capable.49b A popular example is the QqTOF, which is commonly used to
identify unknown metabolites in complicated matrices. Mass spectrometry is particularly useful
for metabolomics research because a wide array of compounds can be detected and analyzed in a
single scan. When in full-scan mode, while a researcher may be looking to analyze a specific
compound, they can also identify and analyze other sample components.
For example, when analyzing a complicated matrix (e.g. blood plasma) for drugs, a
researcher may come across a peak at m/z 207.145 in positive ion mode.53 Using the exact mass,
the molecular formula is determined with confidence to be C13H18O2. Even with the molecular
formula, more information is needed to confidently identify the compound among the C13H18O2
isomers. This could be achieved through other methods such as NMR, or within the same run with
tandem mass spectrometry (MS/MS). The ability to gain formula and fragmentation data in a single
run is one of the major advantages for using HR-MS for metabolomics. Therefore, the analyst can
isolate and fragment the unknown peak, and be able to confirm that it is ibuprofen by the loss of
m/z 46.013 corresponding to formic acid.53 Additionally, several databases exist to compare
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experimental data to standards to gain an extra level of confidence in identification. The summary
of identification levels for metabolites is shown below in Figure 2.3.54

Figure 2.3:
A table summarizing the confidence levels for identification of metabolites and the
requisite data requirements. Reproduced from: 54

In mass spectrometry, signal is not only proportional to concentration, but to ionization
efficiency as well.48,

55

Therefore, internal standards play an extremely important role in

quantitation. At minimum, a compound or compounds with comparable ionization efficiency to
the analyte(s) of interest should be used. However, the best internal standards are ones that have
identical ionization efficiency compared to the analyte, and in mass spectrometry, these are
isotopically-labelled versions of analytes with at least a 3 Da mass difference from the unlabeled
compound.56 With this technique, the mass spectrometer can easily distinguish between the
compounds because of their different mass-to-charge ratios, even after accounting for peak overlap
and/or naturally-occurring mass shifts from isotopes.46 Common labelling techniques selectively
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label H or C atoms with heavy D or

13

C.57 If lower cost is desired, compounds with similar

structures to the analyte can also be used in place of isotopically-labelled compounds, although
this introduces the potential for ionization efficiency differences.57a
Quantitative mass spectrometry, particularly HR-MS, has wide-reaching applications in
fields such as toxicology, environmental science, pharmacology, and others. The exact mass data
obtained from HR-MS leads to much higher specificity of analytes vs. matrix components
compared to low-resolution mass spectrometry.58 This means that quantitation can be done with
confidence that signal from a particular m/z is only coming from the analyte of interest and not
another compound in the sample. In addition, sensitivity of high-resolution mass spectrometers is
very high and quantitation at nanomolar or sub-nanomolar levels is routine.59 In most instances, a
separation technique such as GC, LC, or solid-phase extraction (SPE) is used prior to quantitative
MS, especially when analyzing a complicated sample matrix. This allows for samples varying
from bodily fluids, soil, hair, foodstuffs, etc. to be separated and identified based on both polarity
and mass-to-charge, as well as eliminating interferences from the sample matrix.60 The majority
of workflows use targeted screening, meaning the analytes of interest are at least somewhat known
and the experimental conditions are tailored for detection and quantitation of those analytes. There
are countless examples of this in the literature including but not limited to qualitative identification
of rodenticides in whole blood61, detection and quantitation of date-rape drug GHB in human
hair62, quantitative determination of the antifungal natamycin in wine63, and detection of
polycyclic aromatic hydrocarbons (PAHs) in smoked meats and edible oils64.
In addition to targeted screening, many HR-MS instruments can provide qualitative and
quantitative data for most ionizable compounds in a sample in full-scan mode. Because the exact
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mass information can yield molecular formula and fragmentation can give clues about molecular
structure, previously unknown compounds in a sample can be identified.60, 65 In many cases,
spectra are compared to those in large databases for an extra level of confidence in identification.66
These non-targeted analyses are useful for identifying novel natural products in biological
samples67, novel metabolites in humans and other organisms68, contaminants and xenobiotics in
food69, and many more.

Mass Spectrometry Elevated Energy (MSE)/ Broadband Collision-Induced Dissociation (bbCID)

As an alternative to MRM, mass spectrometry elevated energy or broadband collisioninduced dissociation is a form of tandem mass spectrometry in which the instrument alternates
between high and low collision energy, demonstrated in Figure 2.4. Under low collision energy
conditions, a high-resolution mass spectrometer can display the exact mass and a chemical formula
can be inferred. Under high collision energy conditions, fragmentation will occur and can be used
to determine structural characteristics. Therefore, full-scan and MS/MS data is gathered in a single
run. Another huge advantage of using MSE analysis is that exact mass and fragmentation data are
obtained for each ion in the selected mass range. This is different from SRM or MRM analyses
(discussed above in the LC-MS section) in which precursor ions are selected while discarding
extraneous ions. The higher informational content of MSE scans is advantageous for complex or
unknown samples.
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Figure 2.4:
An instrument schematic showing the cycling between high and low collision
energies during an MSE experiment. Reproduced from: 70

For example, after separation by LC, MSE was used to analyze gelatin in commercial dairy
products.71 By combining the high mass accuracy of the ESI-Q-TOF-MS with the wealth of
indiscriminate fragmentation data obtained by MSE scans, the method was able to differentiate
gelatin produced from bovine and porcine in commercial cheese, yogurt, and ice cream. As gelatin
is a protein, the unique peptide signatures following trypsin digestion were used as biomarkers for
identification. Similarly, in another food science study, Lycium ruthenicum fruits were analyzed
by MSE on the ESI-Q-TOF-MS to identify polyphenols in order to subsequently study their
antioxidant activity.72 These workflows are also extremely applicable to the health science fields.
In studies of chronic kidney disease, rats were dosed with renal-failure-inducing doses of adenine
and their kidney tissues were analyzed by HR-MS to determine metabolic biomarkers of the
disease.73 In this non-targeted metabolomics study, all ions were considered and those appearing
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in adenine-dosed rats and not in control rats were considered potential renal failure metabolites.
MSE is particularly useful in this type of experiment because unknown ions could be identified by
their intact mass and fragmentation in a single run by alternating between high and low collision
energy. Using this workflow, 12 biomarkers for renal failure were identified in negative ion mode
and assigned to a biochemical pathway, yielding a wealth of information about the biology of this
disease. Additionally, a similar workflow investigated the therapeutic effect of Porta cocos
epidermis through the metabolic signature of treated and untreated rats.74 These and other
examples of untargeted metabolomic studies using MSE significantly improve ease and time while
still collecting the same quality information as other HR-MS workflows.70

Figure 2.5:
Example spectra reproduced from reference (70) showing the difference between
high and low collision energy spectra for xanthuric acid. While the low collision energy spectra
mainly shows only the intact ion, the high collision energy one also shows various fragments useful
for identification and structural elucidation.

31

The studies addressed so far all comprise complicated sample matrices, but HR-MS, and
MSE in particular, can also be used for general identification purposes. Another study combined
both MS/MS and MSE to confirm the identities and elucidate the fragmentation patterns of illicit
drugs, and their metabolites and degradation products.59 For many of the illicit drugs studied, lowresolution mass spectrometry data has already been obtained. However, there is some debate about
the completeness of the data and the interpretation of the mass spectra. The high-resolution data
was able to confirm the fragmentation patterns elucidated from low-resolution experiments, and
MSE improved the workflow speed by eliminating the need to isolate and fragment ions
individually (like in MS/MS).

Method Development and Validation

Assay development and validation is often a long and arduous process, with many variables
to consider. Several governing bodies, such as the US Food and Drug Administration (FDA) and
International Conference on Harmonisation (ICH) have created guidelines for scientists in the
pharmaceutical industry and academia to follow to promote uniformity in analytical assays. 75
When developing an analytical assay, the principle and scope need to be determined first. Enzyme
inhibition assays generally measure, either directly or indirectly, the formation of a product or
depletion of a substrate. Depending on the type of assay, the procedure could be transferred for
use with other enzymatic reactions as well. For example, the work presented here directly assays
substrates and/or products by HPLC, MS, or LC-MS, techniques that are widely used and
applicable to a variety of biologically relevant compounds. This is in contrast to many existing
enzymatic assays, known as coupled enzyme assays, which measure the product of a secondary
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enzyme reaction and stoichiometrically relate it back to the analyte of interest. Enzyme inhibition
assays can also be continuous or discontinuous (end point) depending on whether samples are
analyzed continuously or at discrete intervals along the reaction progression after a quenching step.
Assays that employ separation techniques like LC or LC-MS are discontinuous assays.76
Once a method type is chosen, there are factors related to the assay conditions that need to
be optimized. Some are related to the operating parameters of the reaction, such as buffer salt,
ionic strength, temperature, incubation time, and pH. Optimization at this stage ensures that the
reaction is actually proceeding in the intended direction with reasonable speed and helps reduce
artifacts. Other factors relate to the analysis method itself; for example, in LC-MS the stationary
and mobile phases, separation method, LC-MS interface, and MS instrument method all need to
be optimized to be compatible with analytes and be quantitative. The sample preparation protocol
also requires optimization, both to properly end the reaction (quench) and to make the samples
ready for analysis. Sample preparation is an extremely important aspect of LC, LC-MS, and MS
analysis as some components of enzymatic reaction solutions are incompatible with those
techniques. For example, when using HPLC, enzymes must be removed by either filtration or
precipitation because they will clog HPLC columns; and certain reagents such as quench reagents,
buffers, and salts will not electrospray and need to be removed before ESI-MS.77
To be robust and quantitative, assays must contain the appropriate standards and controls.
Various concentrations of the analyte(s) of interest must be prepared to obtain standard curves for
quantitation. In addition, positive and negative controls are needed to elucidate artifacts from the
reaction or sample matrix. A negative control is a sample in which no response is expected, such
as one with no substrate or enzyme present. In a positive control, on the other hand, a response is
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expected and tests if your assay is able to measure the reaction signal. When studying enzyme
inhibition, a positive control in which no inhibitor is present is needed to show the typical way the
enzymatic reaction will proceed. Each experimental run requires both negative and positive
controls.
Before being used for quantitation of analytes in real samples, all methods must go through
several validation steps. Method validation defines the conditions under which the assay is
applicable, the accuracy and precision of measurements from the assay, and assay robustness and
reproducibility. Of fundamental importance to method validation is to establish method selectivity,
the ability to distinguish the analyte(s) from other components in the sample. Blank analyses of
sample matrix should be evaluated for extraneous peaks that could interfere with analyte
quantitation either by coelution or signal depletion. Additionally, the signal that is being
quantitated must be confirmed to be from the analyte. Selectivity should be confirmed for each
analyte to be quantitated down to the lower limit of quantitation. In LC, MS, and LC-MS unique
m/z ratios and retention times are used for identity, and a signal-to-noise ratio of three constitutes
the lower limit of quantitation (LLOQ).
Standard curves evaluate the linearity of a method by measuring the signal intensity vs.
analyte concentration. The calibration curve should include a zero-concentration sample and 4-6
non-zero concentration samples, all prepared in sample matrix. The series of samples of increasing
concentration are measured in triplicate and successful linearity is defined as an R 2 > 0.99. If the
curve passes, it can be used for subsequent quantitation of the analyte in unknown samples.
Calibration curves are also important in evaluating the linear dynamic range of a method, the range
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over which signal will be proportional to sample concentration. Samples with concentrations
outside the range of linearity should not be quantitated with the calibration curve.
Another important method benchmark is a high accuracy and precision in signal and
concentration from the method. Precision is analyzed by performing replicate analyses of standard
samples and evaluating the percent relative standard deviation (%RSD) of retention times and peak
areas. There are two subsets of precision: intra-batch, inter-batch (intermediate). Intra-batch
precision, also called repeatability, is evaluated in by completing replicate analyses within a single
analytical experiment; whereas inter-batch precision is evaluated over time and under varying
experimental conditions (e.g.: analyst, equipment, reagent lot, etc.). In both cases, precise methods
are those in which the deviation is less than 15%. On the other hand, accuracy compares the
quantitative data obtained from a sample to the known concentration and measuring the deviation.
Accuracy is established by doing replicate analyses of samples with known concentrations of
analytes. The concentration of analyte calculated from the method should be within 15% error
from the true value for the method to be considered accurate. Both precision and accuracy are
extremely important and should be evaluated periodically throughout the use of the method.

In vitro Compound Screening for Target Affinity

Modern organic synthesis techniques for drug discovery often lead to libraries of thousands
of compounds that need to be tested against the intended target. Therefore, analytical techniques
with high throughput and sensitivity are necessary. Assays studying enzyme-substrate or enzymeinhibitor binding can be conducted in vitro (in solution) and binding constants obtained. The most

35

common experimental procedure is to incubate the enzyme and substrate under biological
conditions and study reaction aliquots at different time points, obtaining the reaction velocity.78
When these experiments are done for various concentrations of substrates and the reaction
velocities are plotted versus substrate concentration, a Michaelis-Menten plot with a corresponding
Michaelis constant (Km) can be obtained for that enzyme-substrate interaction.79 When inhibitors
are added to the reactions at varying concentrations, inhibition constants (Ki) are elucidated that
describe the strength of binding between the enzyme and inhibitor. And by modifying the data to
form Lineweaver-Burk plots, the inhibition can be described as competitive, non-competitive, or
mixed.80 However, a strong binding affinity to the target enzyme does not guarantee that the
compound will be a potent inhibitor. However, in vitro screening methods can significantly narrow
the number of compounds that are tested further for efficacy by in vivo tests.81

Figure 2.6:
The prototypical Michaelis-Menten curve (bottom left) and the Michaelis-Menten
equation (left), as well as their double reciprocal transformations. Reproduced from: 81
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Initial velocity determinations are made by measuring the rate of product formation over
time before the reaction has reached equilibrium. Then those initial rates are plotted vs. their
respective concentration of substrate to form a Michaelis-Menten curve, which eventually
asymptotically approaches Vmax. Vmax is the point at which all binding sites on the enzyme are
occupied. The substrate concentration at which 50% of Vmax is reached is known as the MichaelisMenten constant, Km. The Km value is a measure of binding affinity, with lower Km values
indicating stronger enzyme-substrate binding. The Km value can also be determined graphically as
the x-intercept of a double reciprocal plot (also known as a Lineweaver-Burk plot).81
Michaelis-Menten experiments can also be used to determine inhibition constants, or Ki
values. The presence of inhibitors the Km and/or Vmax value, which is very noticeable on a
Lineweaver-Burk plot. Competitive inhibitors affect the Km of the enzyme-substrate interaction
(making the binding weaker) and will shift the x-intercept of a double-reciprocal plot toward zero.
On the other hand, uncompetitive inhibitors, which do not directly compete with the substrate for
space in the enzyme binding site, will increase binding affinity and therefore shift the x-intercept
away from zero. They will also decrease the Vmax value of the reaction. Finally, non-competitive
inhibitors, which affect enzyme activity by binding to a non-binding site on the enzyme, do not
affect the Km of the interaction (no change in x-intercept) but will lower the Vmax. Therefore, by
doing Michaelis-Menten experiments with inhibitors at varying concentrations it is possible to
simultaneously the type of inhibitor (competitive, uncompetitive, or non-competitive) and the
inhibition constant (Ki).81
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CHAPTER 3
COMPARISON OF REVERSED-PHASE, ANION-EXCHANGE, AND HYDROPHILIC
INTERACTION HPLC FOR THE ANALYSIS OF NUCLEOTIDES INVOLVED IN
BIOLOGICAL ENZYMATIC PATHWAYS
Introduction

Nucleotides are an important class of biological molecules that play a variety of roles such as
acting as the building blocks for DNA and RNA81-82, storing and releasing chemical energy83, and
playing integral roles in enzymatic reactions21a, 84. Therefore, there is a lot of interest in developing
methods capable of quantitating nucleotides in a variety of sample matrices. High performance
liquid chromatography (HPLC) is a very common and effective technique for analyzing biological
samples and separating analytes based on their relative polarities85. Nucleotides contain between
one and three phosphate groups that are negatively charged at pH slightly above 2 82a.
Consequently, HPLC method development focuses on interactions between the stationary phase
of the column and the phosphate group(s) of the nucleotides. In addition to separation by HPLC,
electrospray ionization-mass spectrometry (ESI-MS) is often required for definitive peak
identification and more sensitive quantitation than spectrophotometric detection46, 86. For this
reason, another important focus of HPLC method development is MS compatibility.
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Of particular interest is the role of nucleotides and other phosphate-containing compounds in
enzymatic reactions. As the primary biological energy carrier, adenosine triphosphate (ATP) and
its dephosphorylated counterpart, ADP, are heavily involved in biological systems including
phosphorylation reactions83a. The primary focus of our work is to develop effective, highthroughput, and robust LC-MS methods to test the efficacy of potential antimicrobial compounds.
Several of the pathways and enzymes of interest involve phosphate-containing compounds. One
such pathway is the methylerythritol phosphate (MEP) pathway, which was introduced in Chapter
1, and that produces isoprenoid precursors in eukaryotic bacteria and some plants87. As isoprenoids
are essential to bacterial survival17a and the MEP pathway is not present in humans, it is an
excellent target for antibiotic development21a, 88. The main enzymes of interest are IspD32, 89, IspE,
and IspF30-31, 90 – all of which catalyze reactions including nucleotides and similar compounds (see
Figure 1.2 in Chapter 1).
Also introduced in Chapter 1 was another enzyme of interest for antibiotic development:
fructose bisphosphate aldolase, or simply aldolase. Aldolase catalyzes the reversible cleavage of
fructose 1,6-bisphosphate (FBP) into dihydroxyacetone phosphate (DHAP) and glyceraldehyde 3phosphate (G3P) in the glycolysis (forward reaction) and gluconeogenesis (reverse reaction)
pathways (Figure 1.5 in Chapter 1)33b, 34, 35b, 38, 91. As these pathways are involved in the production
and metabolism of glucose, they are essential for the survival of most organisms34, 91a, 91c, 92.
Aldolases are divided into two categories based on mechanism of action: class I and class II38, 93.
Class I aldolases are found in animals, including humans, and use a Schiff base intermediate on a
lysine residue33b, 34, 37, 91b, 91c. This is distinct from class II which use Zn2+ ions that bind to a
carbonyl group in the active site33b, 35b, 91. These aldolases are found in bacteria, and are a strong
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target for antibacterial drugs since there is little sequence homology between the two classes33b, 34,
91a, 92

. Assays to study in vitro aldolase activity are typically coupled to glycerophosphate

dehydrogenase and measure the conversion of NADH to NAD+ at 340nm33b, 34, 37, 91-94. LC-MS
analysis eliminates the need for coupled enzyme assays, significantly reducing costs. The standard
nucleotides studied here are secondary reactants and products of the IspE and IspF reactions of the
MEP pathway. Due to the expense and instability of MEP pathway substrates, analysis of
secondary reactants is a useful alternative for in vitro studies. Our goal is to develop effective and
high-throughput separations for real-time analysis of enzymatic reaction samples involving
phosphate-containing analytes - such as the MEP pathway and aldolase - both in vitro and in vivo.
Strong anion exchange (SAX) HPLC caters to the strongly anionic nature of nucleotides by
using a positively-charged stationary phase containing a quaternary amine moiety95. The
phosphate group(s) of the nucleotides form charge-charge interactions with the stationary phase to
gain retention and are eventually eluted in one of two ways: displacement by a strong anion such
as chloride or a pH switch to modify the chemistry of the nucleotide96. For example, the sugarnucleotide product of the antibacterial target IspD enzymatic reaction was analyzed from a reaction
mixture using a 0-500 mM NaCl gradient89. In general, optimum resolution is achieved when using
a steep gradient. However, this approach rules out the possibility of a subsequent MS analysis as
salt concentrations for elution are generally in the high-millimolar to molar range48. Some groups
have attempted to use post-column online desalting as a means of reducing the salt concentration
prior to electrospray mass spectrometry and achieving sufficient MS signal97.
A majority of LC-MS methods utilize reversed-phase HPLC which contains a non-polar
stationary phase such as octadecyl (C18)-bonded silica. On the surface, this seems counterintuitive
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for retention and resolution of phosphate-containing nucleotides. Effective separation of
nucleotides necessitates the use of ion-pairing (IP) reagents to neutralize the charge and optimize
retention98. Tetrabutyl ammonium bisulfate was used by Meyers et al. as a mobile phase additive
to separate nucleotides in the IspF reaction of the MEP pathway. Although this method provided
a short and effective separation scheme using a “rocket” column, a short, high-load column with
dimensions 53x7mm, and a high mobile phase flow rate, it did not use a volatile ion-pairing agent
and cannot be coupled to MS31. However, using low concentrations of volatile ion-pairing reagents
such as triethylamine99 or dibutylamine100 can counter this effect enough to give acceptable MS
signal. Odom et al. performed IP-RP LC-MS analysis with success using tributylamine. However,
as is often the case with ion-pair RPLC, a relatively longer equilibration time is required with
gradient elution and, in this case, it led to a very long runtime not suitable for near real-time
analysis32.
As described previously in Chapter 2, hydrophilic interaction HPLC (HILIC) is a subset of
normal phase chromatography, combining separation power from the liquid-liquid partitioning
between the polar, solvated stationary phase and the water-deficient mobile phase with hydrogen
bonding and ion exchange on the surface of the stationary phase to achieve retention of polar
analytes and seamless MS compatibility40. A variety of HILIC stationary phases are available,
each with unique properties and+ suited for different analytes41a. Because of the interplay between
partitioning and ion-exchange in the HILIC retention mechanism and the wide range of columns
offered, finding the optimum separation scheme can be challenging. Due to the aqueous layer of
the mobile phase solvating on the surface of the relatively polar stationary phase, HILIC stationary
phases often suffer from retention time drift and peak tailing affecting the robustness and
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reproducibility of HILIC methods41a. Retention and separation of nucleotides can be achieved
using amino-101 or amide-bonded102 silica phases, or zwitterionic phases103 containing sulfonates
and quaternary amines. In most cases, when retaining ionic analytes, a stationary phase oppositelycharged is used. However, the recently developed electrostatic repulsion-hydrophilic interaction
chromatography (ERLIC) can separate highly charged analytes by utilizing repulsion from a likecharged stationary phase.104 ERLIC has been used for several applications including the separation
of peptides, nucleic acids and nucleotides, and carboxylates.104-105
In recent years, mixed-mode chromatography techniques have been utilized for difficult
separations. Mixed-mode methods add a secondary stationary phase modality to increase resolving
power. For organic anions such as the phosphate-containing compounds of interest here, a
combination of reversed-phase and anion-exchange or hydrophilic interaction and anion-exchange
are common. For example, sugar phosphates, including structural isomers, have been effectively
separated using a combination of weak anion exchange and reversed-phase under HILIC elution
conditions.106 Similarly, nucleic acid and oligonucleotide separations were investigated on several
ionic-hydrophobic stationary phases to determine the optimum support material; by fine-tuning
the hydrophobicity of the stationary phase, several large oligonucleotides (80-90 chain length)
were able to be separated.107
In this chapter, separation of nucleotides is performed with ion-pair RPLC, anion exchange,
and HILIC mode of liquid chromatography. The performance of stationary phases in these modes
of chromatography and their ability to differentiate nucleotides is compared. The robustness of the
three methods was also compared with inter and intraday retention drift. The utility of FructoShellN HILIC column was further explored for in vitro analysis and quantitation of phosphates in
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enzymatic pathway reactions. The efforts led to a robust, fast, and MS-compatible isocratic method
for separation of nucleotides.
Materials and Methods

Instruments

All HPLC analysis was done at room temperature on an Agilent 1100 HPLC system with a
multiwavelength detector (MWD) set at 260 nm. For each run, 20 μL of sample was injected into
the HPLC. Retention time data from five identical runs were analyzed over the course of four days
to investigate intra- and interday retention time drift. LC-MS analysis was conducted on a
Shimadzu 8030 UHPLC (Nexera)-QqQ system.

Chemicals

5’- adenosine triphosphate (ATP) trisodium salt hydrate, 5’- guanosine monophosphate (GMP)
disodium salt, 5’- cytidine monophosphate (CMP), and 5’- adenosine diphosphate (ADP) sodium
salt were purchased from Sigma (St. Louis, MO). 5’- cytidine triphosphate (CTP) disodium salt,
D-fructose 1,6-bisphosphate trisodium salt octahydrate (98%), acetonitrile (HPLC grade),
methanol (HPLC grade), acetic acid (glacial), phosphoric acid (85%), formic acid, triethylamine
(TEA), sodium chloride (NaCl), ammonium acetate (>99%), and sodium phosphate monobasic
(anhydrous) were purchased from Fisher (Chicago, IL). All water used in experiments was filtered
with an in-house Milli-Q 18MΩ.cm R-O system (EMD Millipore, Billerica, MA).
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Methods
Ion-pair, reversed-phase (IP-RP) HPLC

The IP-RPLC method was developed based on previous reports by Klawitter et al.100 Analysis of
0.1 mg/mL GMP, CMP, ADP, ATP, and CTP in starting mobile phase was carried out using a
Hydro-RP C18 column (150x4.6 mm, 5 μm, Phenomenex, Torrance, CA). The elution gradient
used a mixture of two solvents: 0.1M triethylammonium acetate (TEAA) buffer at pH 5.5 (A) and
methanol (B). After initial column equilibration at 92/8 (v/v) A/B, the mobile phase fraction was
held at 8% B for 1 min, then linearly increased to 27% B over 12 min, increased to 100% B over
2 min, held at 100% B for 4 min, and decreased to the initial mobile phase 8% B over 1 min,
followed by a 15 min re-equilibration period. The flow rate throughout the 20-min run was 700
μL/min.

Strong-anion exchange (SAX) HPLC

For this analysis, the 0.1 mg/mL nucleotide mixture was dissolved in DI water. Separations utilized
a Phenosphere SAX column (150x3.2 mm, 5 μm, Phenomenex, Torrance, CA) and a mobile phase
consisting of 2 mM sodium phosphate monobasic pH-adjusted to 2.5 with phosphoric acid (A) and
the idenitical pH 2.5 with 1 M NaCl (B). Separation of the nucleotides was achieved in a 30-min
run with a column flow rate of 350 μL/min. The gradient elution scheme began after initial
equilibration at 0% B for 5 min, then up to 40% over 10 min, followed by an increase to 60% over
6 min, then up to 100% B over 3 min, 100% B for 4 min for a column wash, back down to 0% B
over 2 min, followed by re-equilibration for 10 min.
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Hydrophilic Interaction (HILIC) HPLC

The HILIC runs analyzed a mixture 0.1 mg/mL CTP, CMP, ADP, ATP, GMP in 55/40/5
acetonitrile/water/methanol on a FructoShell-N HILIC core-shell column (100x3.0 mm, 2.7 μm,
AZYP, LLC, Arlington, TX) graciously provided free-of-charge by the company. The 20-min
isocratic run used a mobile phase of 85/15 (v/v) of 55.5/39.5/5 Acetonitrile/water/methanol with
100 mM ammonium acetate pH 6.6 overall (A) and acetonitrile with 0.1% formic acid (v/v) (B) at
425 μL/min. For LC-MS analysis, the column flow rate was increased to 800 μL/min and
nucleotide m/z values were monitored in negative mode using selected ion monitoring (SIM) over
the 10-min run time. A sample of 2 mM FBP in starting mobile phase was analyzed under the same
chromatographic conditions with MS/MS detection of dephosphorylated FBP (m/z 339.1>241.1;
CE -35.0V) in selected reaction monitoring (SRM) mode.
Prior HILIC analyses included those done on zwitterionic (Nucleodur HILIC by MachereyNagel), amide (Xbridge amide by Waters), bare silica (Luna silica by Phenomenex), and amino
(Selectosil NH2 by Phenomenex) columns. A mixture of the same five analytes listed above were
analyzed on a Waters XBridge Amide column (2.1 x 30 mm, 3.5 μm particle size) with an isocratic
elution scheme of 65/35 MeOH/100 mM ammonium formate buffer pH 4.01 at 0.2 mL/min.
Additionally, the Nucleodur HILIC column (3.0 x 100 mm, 3 μm particle size) was used to separate
CDP, ADP, and ATP in an isocratic run with 70/30 ACN/10mM ammonium bicarbonate buffer
pH 7.0 at 0.5 mL/min. A quick retention test of ATP was conducted on a Luna Silica column (2.0
x 100mm, 3μm particle size), but the results were not favorable, and development did not continue.
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Results
IP-RP

Reversed phase liquid chromatography (RPLC) is the de facto standard in HPLC methods due to
its high sensitivity, robustness, and availability of a wide selection of stationary phases. However,
most RPLC stationary phases are based on Octadecyl bonding which offer poor retention to polar
analytes. In many cases, highly polar analytes, such as nucleotides, may experience pore expulsion
where they are unable to access the surface area inside the pores and elute in void volume. Addition
of ion-pairing agents is an effective remedy to retain these polar molecules. For separation of
nucleotides, this particular method utilized a high concentration of 0.1 M triethylamine (TEA) to
separate five nucleotides commonly found in biological reactions: CMP, CTP, GMP, ADP, and
ATP. This method was able to distinctly separate all five analytes with no coelution and offered
the best resolution of all the methods tested (Figure 3.1).
Nucleotide Separation by Ion-Pair Reversed-Phase HPLC
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Figure 3.1:
Representative HPLC chromatogram showing separation of five nucleotides by IPRP HPLC. This chromatogram excludes the wash stage of the gradient.
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At low concentrations, triethylamine is volatile enough for ESI-MS analysis, but prior
experiments showed that low concentrations of TEA (~10 mM) did not give sufficient separation
of nucleotides (data not shown). Interday variability in retention times was between 3-7% (Table
3.1) and is likely due to mobile phase degradation, mixing problems, or solvent evaporation.
Intraday retention times also varied, with relative standard deviations reaching 4-8% on Day 3
compared to 1-3% on Day 2 and <1.5% on Day 4 (Table 3.2). Such drift is not ideal for increasingly
relied-upon automated analyses in which the instrument software selects peaks for identification
and analysis based on retention time and hence this method is not robust.
Table 3.1:
Interday average retention times and variabilities for ion-pair reversed-phase HPLC
over four days.
Analyte Average
tr (min)
CMP
6.94
CTP
3.08
GMP
7.70
ADP
4.54
ATP
3.80

sd

%rsd

0.34
0.10
0.34
0.31
0.17

4.85
3.09
4.38
6.75
4.50

Table 3.2:
Intraday relative standard deviations in retention times for nucleotides analyzed by
IP-RP HPLC.
Analyte
CMP
CTP
GMP
ADP
ATP

Day 1 %RSD
2.14
1.01
2.56
2.11
2.04

Day 2 %RSD
1.88
1.02
1.47
2.58
0.89

Day 3 %RSD
5.98
4.29
5.82
7.74
8.36

Day 4 %RSD
0.91
0.56
0.89
1.19
1.16
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HILIC

After preliminary screening of several commercially available HILIC columns such as bare silica,
zwitterionic, amino, and amide, they provided poor peak symmetry and/or poor resolution (see
example chromatogram in Supplemental Information). This led to choosing FructoShell-N HILIC
column108, a HILIC stationary phase containing a native cyclofructan 6 moiety (Figure 3.2) which
allows for retention of ionic analytes by an ion-exchange mechanism made possible by docking a
cation (such as K+, Ba2+, or NH4+) into the crown ether core109. Figure 3 shows that the native
cyclofructan stationary phase bonded to 2.7 μm core-shell silica support particles and ammonium
acetate buffer led to low peak asymmetry which improved sensitivity and resolution.

Figure 3.2:
Structure of the cyclofructan stationary phase used in the FRULIC-N and
FructoShell HPLC columns. The crown-ether center is able to dock cations (such as ammonium,
which was used in this study) and act as an ion-exchanger for retention of acidic analytes.
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Of the other HILIC columns tested, although the Xbridge Amide column offered a fast
elution scheme, the short size (30mm length) did not allow for adequate separation of analytes
(Figure 3.3). The column dimensions of the Nucleodur column are much more similar to those of
the FrustoShell column, making the results a better fit for comparison. The best separation was
achieved with a mobile phase of 70/30 ACN/10mM ammonium bicarbonate buffer pH 7.0 run
isocratically at 0.5 ml/min (Figure 3.4). While the separation was very good with this column,
there were issues with retention time stability. This issue was alleviated with overnight column
equilibration (Figure 3.5), but this technique is cost-prohibitive and extremely time consuming.
With buffers such as ammonium acetate instead of ammonium bicarbonate, tailing increased and
severely impacted resolution. Finally, a bare silica column was briefly investigated, but as it is
mainly applicable to basic analytes, the retention of the nucleotides was very low and peak tailing
was prominent.

XBridge Amide Column: CMP, CDP, CTP, ADP, ATP
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Figure 3.3:
elution.

Analysis of five nucleotides on the XBridge Amide column under isocratic
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Peak Drift in CDP, ADP, ATP Separation
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Figure 3.4:
Repeatability analysis of a CDP, ADP, and ATP separation under isocratic
conditions after a one-hour initial column equilibration.

The FructoShell-N method yielded the lowest intraday peak drift values (Table 3.3) despite
retention drift being a common issue with other HILIC phases. One contributing factor was the
use of a premixed organic/aqueous mobile phase A to increase temperature stability and prevent
gas bubbles from forming. Additionally, the method offered short run time with an isocratic elution
scheme, meaning samples can be continuously analyzed with no column re-equilibration. Table
3.4 shows that interday peak drift was generally <5% (with the exception of GMP) and could likely
be improved by preparing fresh mobile phase daily. Interday data show a small but consistent
downward shift of all analyte peaks.
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Figure 3.5:
Repeated analysis of CMP under the same chromatographic conditions as those is
Figure 3.4, but with overnight column equilibration.
Nucleotide Separation by HILIC HPLC
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Figure 3.6:
Representative HPLC chromatogram of five nucleotides analyzed on the
FructoShell HILIC column under isocratic conditions at 0.425 mL/min.
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Table 3.3:

Intraday retention time variability from HILIC analyses given as %RSD values

Analyte
CMP
CTP
GMP
ADP
ATP

Table 3.4:
HILIC

Day 1 %RSD
0.13
0.62
0.26
0.64
0.72

Day 2 %RSD
0.31
0.49
0.27
0.47
0.51

Day 3 %RSD
0.82
2.49
0.43
3.15
2.68

Day 4 %RSD
0.17
0.06
0.13
0.23
0.09

Average retention times and variabilities for interday analysis of nucleotides by

Analyte Average
tr (min)
CMP
9.79
CTP
19.91
GMP
8.84
ADP
14.28
ATP
16.63

sd

%rsd

0.46
0.63
0.47
0.62
0.59

4.73
3.18
5.29
4.36
3.55

To test the ESI-MS compatibility of the method, the analysis was performed on a Shimadzu
8030 UHPLC-QqQ LC-MS system. MS detection of nucleotides was conducted in negative ion
mode with selected ion monitoring (Table 3.5). In an attempt to increase throughput, the column
flow rate was increased from 425 μL/min to 800 μL/min. Results show that the increased flow rate
decreased the run time from 20 min to 10 min while maintaining resolution between the five
analytes (Figure 3.7). It should be noted that under current LC-MS conditions, some ATP
undergoes in-source fragmentation forming ADP at the same retention time. This is a common
issue in the analysis of nucleotides due to the lability of phosphate groups and the high voltages
used in the MS source and ion guides. Further experiments will focus on optimizing conditions to
prevent in-source dephosphorylation of the nucleotide analytes.
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Table 3.5:

The m/z values monitored in SIM(-) LC-MS analysis of nucleotides (Figure 3.7).
[M-H]m/z
322.1
482.1
362.1
426.1
506.1

Analyte
CMP
CTP
GMP
ADP
ATP

SIM (-) LC-MS Analysis of Nucleotides
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Figure 3.7:
LC-MS analysis of nucleotides by a 10 min isocratic elution scheme (0.8 mL/min)
followed by SIM(-) detection of analyte m/z (values given in Table 3.5).

As a means of evaluating the broader applicability of this method to other phosphatecontaining analytes, we tested the retention of fructose bisphosphate – the substrate of aldolase
that contains two non-bridged phosphate groups – under the same chromatographic conditions as
the above experiments. With none of the reactants and products of the aldolase reaction being UV-
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active, chromatographic assays of enzyme activity and/or inhibition must rely on sensitive MS
analysis. Figure 3.8 shows an isocratic run at 0.8 mL/min in which FBP retains on the FructoShellN column and is analyzed by its fragmentation pattern (loss of phosphoric acid). This result is
promising for the development of a sensitive and high-throughput aldolase analysis method as an
alternative to the traditional spectrophotometric assay.

SRM Analysis of Fructose Bisphosphate by LC-MS/MS
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Figure 3.8:
LC-MS/MS spectrum showing retention of fructose bisphosphate on the
FructoShell HILIC column with selected reaction monitoring (SRM) detection.

SAX

Strong anion exchange is a popular choice for HPLC analysis of nucleotides without subsequent
MS analysis. Our analysis used a Phenoshere SAX quaternary-amine stationary phase and a mobile
phase buffered at very low pH of 2.5 to prevent irreversible retention and promote fast elution of
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nucleotides when increasing salt concentration. Even using a steep NaCl gradient, we had
difficulty obtaining acceptable resolution between ATP and CTP (Figure 3.9) with this particular
method. However, the very low interday retention time drift, as evidenced in Table 3.6, allowed
for resolution to remain ≥1.0. Additionally, the intraday %RSD values for CTP and ATP retention
times remained very low, with an average of <2% for both analytes (Table 3.7).

Nucleotide Separation by Strong Anion Exchange HPLC
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Figure 3.9:
Representative chromatogram of nucleotide separation of SAX. Varying degrees of
coelution of CTP and ATP were present in all runs.
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Table 3.6:
Interday average retention times and deviations for nucleotide analytes analyzed by
strong anion exchange HPLC.
Analyte Average
tr (min)
CMP
3.23
CTP
14.57
GMP
4.31
ADP
11.29
ATP
13.54
Table 3.7:
Analyte
CMP
CTP
GMP
ADP
ATP

sd

%rsd

0.03
0.19
0.07
0.14
0.18

0.80
1.34
1.57
1.23
1.30

Intraday variabilities in retention times for nucleotides analyzed by SAX.
Day 1 %RSD
1.11
2.65
3.02
0.49
1.04

Day 2 %RSD
0.81
0.21
1.96
0.28
0.22

Day 3 %RSD
1.52
3.57
2.86
0.89
0.67

Day 4 %RSD
1.10
0.71
2.22
0.71
0.27

Discussion

Separation parameters for each analyte are listed in Table 3.8, with parameters listed for
the developed FructoShell-N HILIC method and IP-RP and SAX method values for reference.
Retention factors (k) demonstrate the degree of retention of an analyte relative to the void time of
the column, and a range of 2-10 is considered optimal. While the experiments described here
analyzed clean samples, unretained compounds from complicated sample matrices could
potentially overshadow these peaks. For the nucleotides analyzed by FructoShell-N, the retention
factors were often greater than 10. While this is not explicitly a problem, phenomena such as peak
broadening tend to be exacerbated as retention increases. However, higher retention is clearly
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better given the eventual goal of analyzing biological samples which will leave a lot of unretained
components.

Analyte
CMP
CTP
GMP
ADP
ATP

Mean tr
(min)
6.92
3.07
7.68
4.52
3.80

IP-RP (n=23)a
αc
Mean Nd

Mean kb

Mean Rse

Mean Sf

2.18
37084
16.68
0.69
-18773
-0.71
1.17
28586
4.18
0.44
1.56
22081
5.98
0.77
2.24
9666
4.69
0.49
HILIC (n=19)
CMP
9.77
7.72
1.12
4951
1.71
0.62
CTP
19.89
16.8
1.21
10465
4.21
0.62
GMP
8.82
6.87
-6084
-0.84
ADP
14.26
11.7
1.52
8294
7.17
0.48
ATP
16.61
13.8
1.18
9675
3.48
0.61
SAX (n=20)
CMP
3.23
0.34
-1704
-0.51
CTP
14.54
5.03
1.09
2865
0.93
0.32
GMP
4.31
0.79
2.32
6458
5.03
0.92
ADP
11.27
3.68
4.67
66092
39.71
1.38
ATP
13.53
4.61
1.26
7016
3.50
0.74
Table 3.8:
Summary of various chromatographic parameters for each nucleotide analyzed by
IP-RP, SAX, and HILIC.
a

1.78
0.23
2.09
0.82
0.52

n = total number of runs for each method

b

Mean k was obtained by subtracting column void time (t0) from retention time (tr) for each run
then taking the mean
α for each analyte is the ratio of k values for adjacent peaks and was not calculated for the firsteluting analyte from each method
c

d

𝑡 2

Mean N was calculated as 𝑁 = 16 (𝑤) then averaged

e

Mean Rs was calculated using the fundamental resolution equation for adjacent, subsequent
peaks
f

Symmetry factors were calculated by the Agilent ChemStation software, and S values for each
run were averaged.
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The reversed-phase separation that we used offered very high efficiency. Ion pairing is
widely known to have this effect because it produces sharp peaks and modulates retention. Our
goal was to model this efficiency with the HILIC method, and when using the FructoShell-N
column, the separation efficiency ranged between about 5000-10000 plates. As mentioned
previously, peak shape (particularly broadening and tailing) is a common problem with HILIC
separations. The core-shell particles utilized in the FructoShell-N column treat this problem by
decreasing the eddy dispersion significantly while also reducing the longitudinal diffusion and
resistance to mass transfer, thereby providing a more homogenous packed bed that provides a
higher performing column. Additionally, the FructoShell-N column is UHPLC capable, and
increasing the column flow rate can be used as a means of decreasing run times (as evidenced in
Figure 3.7), and increasing resolution by improving column efficiency110. Some initial studies have
been done to improve separation by substituting acetonitrile as the organic solvent for
tetrahydrofuran. As THF is aprotic and less polar than acetonitrile, the partition coefficient
between the aqueous and organic layers are greater in this case, theoretically leading to a more
effective separation. The examples of THF/ammonium acetate isocratic and gradient elution
schemes, and high flow rate runs are given in the Supplemental information (Figures 3.10-3.12).
Important to note is that the column used in these studies was 15cm long, so comparisons are made
only to data from the 15cm column. Compared to the isocratic THF/ammonium acetate mobile
phase (3.10), the gradient elution schemes (3.11) provide an increase in separation efficiency by
improving peak shape of late-eluting triphosphates. The impact is even greater when the column
is run in UHPLC mode (3.12) and, as mentioned previously, running at a higher flow rate cuts the
run time approximately in half.
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Column: FructoShell-N 150 x 3.0 mm ID by AZYP LLC
MP: Isocratic, 70/30 THF/100 mM NH4OAc, no pH adjustment
Flow rate: 0.425 mL/min; Wavelength: 260 nm
Instrument: Agilent UHPLC 1290 Infinity II

Figure 3.10:
phase.

Isocratic elution of five nucleotides on a 15cm column with a buffer/THF mobile

Column: FructoShell-N 150 x 3.0 mm ID by AZYP LLC
MP: Gradient, 70/30 THF/100 mM NH4OAc from 0 to 16 min
then 55/45 THF/100 mM NH4OAc from 16 to 20 min. No pH
adjustments
Flow rate: 0.500 mL/min; Wavelength: 280 nm
Instrument: Agilent UHPLC 1290 Infinity II

Column: FructoShell-N 150 x 3.0 mm ID by AZYP LLC
MP: Gradient. 70/30 THF/100 mM NH4OAc from 0 to 14
min then 50/50 THF/100 mM NH4OAc from 14 to 20 min.
No pH adjustment
Flow rate: 0.500 mL/min; Wavelength: 280 nm
Instrument: Agilent UHPLC 1290 Infinity II

Figure 3.11: Sample gradients of THF/buffer to improve separation and peak shape of
nucleotide analytes.
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Column: FructoShell-N 150 x 3.0 mm
ID MP: Gradient. 70/30 THF/100 mM
NH4OAc from 0 to 8 min then 50/50
THF/100 mM NH4OAc from 8-11 min.
No pH adjustment.
Flow rate: 0.800 mL/min; Wavelength:
280 nm

Figure 3.12:

Nucleotide analysis by a shortened gradient in UHPLC mode.

Table 3.9:
Average intraday %RSD values for each analyte for each of the three separation
methods tested.
Analyte
CMP
CTP
GMP
ADP
ATP

SAX average %RSD
1.14
1.79
2.52
0.59
0.55

HILICaverage %RSD
0.36
0.92
0.27
1.12
1.00

IP-RP average %RSD
2.73
1.72
2.69
3.41
3.11

The data in Table 3.9 show that average intraday %RSD for each analyte was generally
<1% for FructoShell-N HILIC. The small drift between runs has important implications for the
development of fully-automated analysis schemes being used in many applications. These results
are in stark contrast to the those obtained from a repeatability analysis of three nucleotides – ADP,
ATP, and CDP – on the zwitterionic Nucleodur HILIC column, seen in Figure 3.4, in which visible
peak drift was observed between six replicate runs and subsequently required overnight
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equilibration (Figure 3.5). Finally, FructoShell-N HILIC is ESI-MS compatible without the timeintensive and expensive desalting efforts required when using the high concentrations of salts and
ion-pairing reagents displayed in these reference methods. It is important to note, however, that
the methods presented here are only a small sampling of the variety of HPLC methods applicable
to organic phosphate analysis. Ion-pair reversed-phase methods are extremely common and are
even sometimes combined with MS when a volatile ion-pair reagent is used in low concentrations,
and the steep gradients often used in ion-exchange methods promote high-throughput.30-31, 89 For
example, inhibition of IspD by fosmidomycin was previously quantitated using an LC-MS/MS
method in which 10 mM tributylamine is used as an ion-pairing reagent with an almost 30-min.
stepwise gradient from 10-60% ACN followed by a 100% ACN column wash on the Hydro-RP
C18 column.32 By using a low concentration of a volatile ion-pairing reagent combined with a RP
column with polar endcapping, matrix effect was largely avoided in this case.
In addition, changes in phase chemistry and column size can make significant changes
toward improving the quality and efficiency of a separation. When the analytes are UV-Vis-active,
an IP-RP or SAX method with good resolution may be the most appropriate analysis technique.
The ultimate goal of this work is to develop an LC-MS method that can be applied across multiple
enzymatic pathways with polar, acidic analytes with little or no intermediate method development
required. Because HILIC does not necessitate the use of high concentrations of salts or ion-pairing
reagents for separation, we chose to focus our method development on that. Based on our initial
method development results from a few of the many HILIC phases offered, we present a strong
case here that FructoShell-N is a promising stationary phase for further research in this type of
applications.
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Conclusions

For decades, HPLC analysis of nucleotides and other phosphates was done by either anion
exchange or ion-pair reversed-phase. However, great care must be taken when interfacing
separation techniques with mass spectrometry, as these methods often require non-volatile mobile
phase additives. Hydrophilic interaction liquid chromatography (HILIC) can alleviate the issues
with AX and RP, but not all HILIC stationary phases are suited for separating strongly ionic
nucleotides. Based on the data presented here and previous evaluations of several HILIC phases,
the FructoShell HILIC column successfully separated the nucleotide analytes from the MEP
pathway via isocratic elution without dramatic peak tailing or co-elution and was able to retain
fructose bisphosphate from the aldolase reaction with no method modifications. In addition,
FructoShell HILIC gave comparable retention time stability to the reference SAX and IP-RP
methods, and was shown to be ESI-MS compatible without desalting. Finally, increasing the flow
rate to reduce run time did not compromise resolution, making this method a good choice for highthroughput UHPLC or LC-MS analysis of phosphate-containing compounds in biological systems
such as the MEP pathway, aldolase, and many more.
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CHAPTER 4
QUANTITATIVE HR-MS: METHOD DEVELOPMENT AND VALIDATION

Introduction

The aldolase enzyme is present in all organisms and this reaction plays a vital role in the
transition between the preparatory and pay-off phases of the glycolysis pathway.81 Glycolysis
converts monosaccharides (primarily glucose) into the biological energy carrier ATP and
precursors for the Krebs cycle or cellular respiration (pyruvate and NADH). The aldolase enzyme
is also involved in gluconeogenesis, essentially the opposite of glycolysis in which glucose is
synthesized to maintain appropriate blood glucose levels.111 Because of the widespread importance
of the pathway in sustaining life, glycolysis enzymes are of scientific interest for mechanistic,
kinetic, and inhibitory studies. The aim of this part of the study is to develop and qualify an ESIMS method, without prior HPLC separation, to be used for in vitro kinetic analysis of the fructose
bisphosphate (FBP) aldolase-catalyzed enzymatic reaction (shown in Figure 1.5 in Chapter 1).
As seen in the Figure 1.5, all of the compounds involved in the aldolase reaction are
phosphates or bisphosphates. Phosphate-containing analytes are great candidates for MS detection
because the phosphate group is anionic at almost any pH.112 Therefore, these compounds can be
analyzed by ESI in negative ion mode without adjusting the pH of the solution. 113 This does not
mean, however, that method development is not necessary. Phosphate groups can readily cleave if
ESI and ion transfer conditions are harsh, including a process known as in-source fragmentation.114
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It is important to optimize intact ion signal while keeping in-source fragmentation to a minimum,
and MS parameters can be tuned to achieve the best balance.
The MS method developed here utilizes a high-resolution ESI-QqTOF system, a schematic of
which is shown in Figure 4.1. HR-MS demonstrates very high sensitivity and mass accuracy,
helping to avoid analyte interference and decreasing the amount of sample needed.115 As
mentioned in Chapter 2, the QqTOF system can distinguish ions with mass differences of 0.001
m/z with a resolving power of up to 60,000.116 In the post-run analysis software, the exact mass
data can be matched to the corresponding chemical formula and compounds of the same nominal
mass are ranked according to mass error.117 An added benefit of the QqTOF is the capability of
MS/MS which when combined with the chemical formula allows the user to confidently identify
analytes based on both formula and structure.118

Figure 4.1:

A schematic showing the components of an ESI-QqTOF-MS. Obtained from: 119
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MS quantitation is based on comparative signal between the analyte and an internal
standard.46 In this case, the analyte of interest is reaction substrate fructose bisphosphate (FBP)
and isotopically-labelled analog, in this case (13C)6-FBP, is the internal standard. The method
development and validation process followed the goals of specificity, high sensitivity, mass
accuracy, linearity, and precision. Guidelines for evaluation of these parameters are provided by
ICH, a procedure which is nearly universally used for analytical methods.75a The MS methods
developed here were designed to meet the guidelines provided by the ICH, and only validation
data for the optimized method is presented.
As part of the method validation process, mass accuracy for the QqTOF-MS was studied
by calculating mass error between the theoretical and experimental m/z values for both the
substrate and internal standard. Identities were also confirmed by MS in both selected reaction
monitoring (SRM) and alternating collision energy (MSE) modes. Once the analytes were
thoroughly identified, a “blank” in vitro reaction sample was analyzed to confirm method
specificity for these analytes.
In order to be quantitative, an assay must exhibit linearity over a useful range of standard
concentrations. Typically, calibration curves must include at minimum: triplicate analyses of five
different standard concentrations. In the case of mass spectrometry, for which concentration is not
easily deciphered by signal intensity alone, FBP signal is normalized against the signal from a
constant concentration of internal standard. The standard curve can also elucidate the linear
dynamic range. To do this, standards over several orders of magnitude of concentration are needed.
The linear dynamic range of an assay is the number of orders of magnitude during which linearity
holds.
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Precision was evaluated as repeatability and two forms of intermediate precision (intraand inter-day). Both are important for constant and long-term data gathering. Repeatability
analyzes at least six replicates of a single sample and reports deviation in both signal and m/z.
Intermediate precision is broken down in several ways: variability on a single day of separate
sample preparations and replicate analysis (intraday), and comparison of the intraday analyses
from more than one day (interday). In this case, data was also gathered for samples analyzed using
a different ESI spray needle – the variability of which can offer insight into method robustness and
transferability.
All of these parameters give insight into the effectiveness of HR-MS for quantitation.
However, the validation data shown here analyzed clean mixtures containing only substrate and
internal standard in reaction solvents. Therefore, because the eventual goal is to apply this method
for quantitation of in vitro reaction kinetics, an example reaction is run using the optimized MS
conditions as a “proof of concept,” to confirm that real, useful quantitative data can be gathered
and applied to enzymatic kinetic reaction models.
Materials and Methods

Chemicals

D-fructose 1,6-bisphosphate trisodium salt octahydrate (98%), ammonium acetate, sodium
chloride, and acetonitrile (HPLC grade) were purchased from Fisher (Chicago, IL). Aldolase from
rabbit muscle was purchased from Sigma-Aldrich (St. Louis, MO). (13C)6-D-fructose bisphosphate
sodium salt hydrate (98%) was purchased from Cambridge Isotope Laboratories Inc. (Andover,
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MA). All water used in experiments was filtered with an in-house Milli-Q 18MΩ.cm R-O system
(EMD Millipore, Billerica, MA).

Instrument Parameters

All samples were analyzed on a Bruker MaXis Plus ESI-QqTOF instrument in negative ion mode
from m/z 100-800. The ESI source parameters were as follows: 210 C dry gas temperature, 8.0
L/min dry gas (N2) flow, 1.6 bar nebulizer gas (N2) pressure, 3.5 kV capillary voltage, and 700V
end plate offset. The QqTOF-MS was tuned as follows: funnel RF 300 Vpp, multipole RF 200
Vpp, collision RF 1000.0 Vpp, ion cooler RF 800 Vpp, isCID (in-source collision-induced
dissociation) 0.0 eV, ion energy 4.0 eV, collision energy 7.0 eV, pre-pulse storage 5.0 μs, transfer
time 100.0 μs. This MS method was used for sample analyses unless otherwise specified.

Mass Accuracy

To evaluate mass accuracy of FBP and the IS, a sample of 0.1 mg/mL of each in 50/50
acetonitrile/10mM ammonium acetate buffer was analyzed using the instrument method above. In
addition, fragmentation experiments were conducted in selected ion monitoring (SRM) mode for
each analyte by isolating the ion and applying 16 eV of energy to q2.

Standard curves

Fructose 1,6-bisphosphate (FBP) at various concentrations between 0.1-500 µM in 50/50 (v/v)
reaction buffer/acetonitrile with a constant concentration of 10 μM (13C)6-fructose 1,6-
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bisphosphate (the internal standard). The reaction buffer used was that of class I aldolase: 10 mM
ammonium acetate at pH 7.6 with 2 mM NaCl. A standard curve for FBP was created by plotting
average normalized signal (arbitrary counts) from triplicate sample analyses vs. concentration
(μM).

Specificity

To simulate a “blank” reaction sample, a solution of 12.7 nM rabbit muscle aldolase (tetramer) in
50/50 buffer/acetonitrile was prepared. The full scan spectrum from this sample was evaluated for
interfering ions at m/z 338.99 or 345.01 +/- 0.01, the m/z values of FBP and (13C)6 -FBP,
respectively.
Repeatability and Intermediate Precision
Repeatability was studied by comparing the m/z values and signal intensities from six replicate
injections of 0.1 mg/mL FBP and 13C-FBP in 50/50 buffer/ACN. The mean, standard deviation,
and relative standard deviation (%RSD) were calculated and reported.
Intermediate precision was evaluated over two days. On each day, three solutions of 0.1
mg/mL FBP and 13C-FBP in 50/50 buffer/ACN were each analyzed twice and the means, standard
deviations, and %RSDs were reported (intraday precision). The data from the two days were
compared to yield interday precision values. An additional experiment on the second day used an
alternative spray needle than the one used for previous experiments. The samples prepared on Day
2 were also used for this experiment and the results were compared to the intraday data from Day
2 (robustness).
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MSE

The instrument method used for MSE was different from the one used for other experiments. In
this case, the ESI source parameters were: 220 C dry gas temperature, 8.0 L/min dry gas (N2) flow,
1.6 bar nebulizer gas (N2) pressure, 3.0 kV capillary voltage, and 500V end plate offset. The
QqTOF tune parameters were: funnel RF 150 Vpp, multipole RF 50 Vpp, collision RF stepped
between 650.0 and 2000.0 Vpp, and ion transfer time ramped between 41.1 and 64.0 μs, isCID 0.0
eV, ion energy 4.0 eV, collision energy 7.0 eV, pre-pulse storage 1.0 μs, transfer time 100.0 μs.
The collision energy was alternated between 7.0 eV (low energy) and 30.0 eV (high energy) for
MSE. The experiment was conducted with a solution of 0.1 mg/mL FBP and

13

C-FBP in 50/50

buffer/ACN.

Results

Mass Accuracy

Full scan and SRM scans for both FBP and 13C-FBP are presented below (Figures 4.3-4.6). The
data show that the m/z values of 338.9922 for FBP and 341.0112 for 13C-FBP. Table 4.1 shows
the comparison between the theoretical calculated exact masses and the measured ones. For both
ions and their fragments, mass accuracy is very high, with the differences in m/z values being
between 1 and 4 mDa and 6-11 ppm. These ions were confirmed as those corresponding to the
negative ion of FBP and

13

C-FBP, [M-H]-, and SRM fragments corresponding to the loss of

phosphoric acid, [M-H3PO4-H]-. Replicate trials show slight variability in the third and fourth
decimal places, so henceforth, FBP will be identified as m/z 338.99 +/- 0.01 and 13C-FBP as 345.01
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+/- 0.01. This range of error also incorporates the theoretical mass values. It is important to note,
however, that these ranges are subject to change over time or with instrument modification. Table
4.2 shows mass accuracy data produced after the spray needle distance was adjusted and
demonstrated a roughly three-fold increase in mass error for each compound and fragment
compared to Table 4.1. Therefore, mass accuracy will be continuously monitored, and the
instrument will be re-calibrated as necessary to keep mass error as low as possible.

Figure 4.2:
Structures and m/z values for the substrate fructose bisphosphate (FBP, right) and
the internal standard (13C6-FBP, left).

70

Table 4.1:

Summary of mass accuracy data.

Name
Fructose
bisphosphate
[M-H]Fructose
bisphosphate
fragment*
[M-H3PO4-H](13C)6-fructose
bisphosphate
[M-H](13C)6-fructose
bisphosphate
fragment**
[M-H3PO4-H]-

Calculated exact Measured
mass (Da)
mass (Da)
338.988772
338.9922

exact Δ (Da)

Δ (ppm)

0.0033

10.11

241.011333

241.0134

0.0021

8.58

345.008356

345.0116

0.0032

9.40

247.031460

247.0330

0.0015

6.23

*The mass difference corresponds to phosphoric acid (exact mass: 97.976898 Da, delta 0.001802)
** The mass difference corresponds to phosphoric acid (exact mass: 97.976898 Da, delta 0.001702)

Table 4.2:

Summary of mass accuracy data after adjusting capillary distance

Name
Fructose
bisphosphate
[M-H]Fructose
bisphosphate
fragment*
[M-H3PO4-H](13C)6-fructose
bisphosphate
[M-H](13C)6-fructose
bisphosphate
fragment**
[M-H3PO4-H]-

Calculated exact Measured
mass (Da)
mass (Da)
338.988772
339.0009

exact Δ (Da)

Δ (ppm)

0.0121

35.78

241.011333

241.0205

0.0092

38.04

345.008356

345.0212

0.0128

37.23

247.031460

247.0404

0.0089

36.19

*The mass difference corresponds to phosphoric acid (exact mass: 97.976898 Da, delta 0.003502)
** The mass difference corresponds to phosphoric acid (exact mass: 97.976898 Da, delta 0.003902)

71

Full Scan of FBP
1000000

[M+Na-2H]
360.9744

900000

-

800000

Intensity (arb)

700000
600000

-

[M-H]
500000 338.9922
400000
300000
200000
100000
0
200

250

300

350

400

450

500

m/z

Figure 4.3:
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Specificity

One of the major benefits of HR-MS is the extremely high specificity. As opposed to a lowresolution method which can only measure exact mass to within about 0.01-0.1, HR-MS measures
exact mass to roughly 0.001 m/z. Because of this, even if interfering peaks are present at the same
nominal mass as the analyte, they will not have the same exact mass. For this method, the matrix
was relatively simple but specificity can also be evaluated by HR-MS for complicated matrices
such as whole blood. Analyzing a complex matrix increases the chances of isobaric ions in MS,
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even in high-resolution mode. The QqTOF-MS, which is capable of obtaining fragmentation data,
allows those isobaric ions to be structurally elucidated from each other.
Specificity for the ESI-QqTOF method was evaluated by studying a sample of 12.7 nM
rabbit muscle aldolase in class I aldolase buffer. This is essentially an aldolase reaction sample
without substrate (FBP) or internal standard (13C-FBP). Figure 4.7 shows a full scan spectrum of
this blank sample and demonstrates that there is negligible signal in the range of m/z 338-346.
Additionally, none of the noise peaks in this range match the exact mass of fructose bisphosphate
(m/z 338.99) or (13C)6-fructose bisphosphate (m/z 345.01), conclusively confirming the specificity
of the method.

Blank: No FBP or IS
1200000

Blank: No FBP or IS
35000

1100000

30000

1000000
Intensity (arb)

25000

Intensity (arb)

900000
800000

20000

15000

10000

700000
5000

600000

0
300

310

320

330

340

350

360

370

380

390

400

m/z

500000
400000
300000
200000
100000
0
200

250

300

350

400

450

500

m/z

550

600

650

700

750

800

76

Figure 4.7:

Full scan of matrix without S and IS
Linearity

For this study, linearity was investigated over three orders of magnitude of fructose bisphosphate
concentration (0.1-500 μM) and under the buffer conditions for both Class I aldolase. Figure 4.8
shows that over the full series of micromolar concentrations, triplicate analyses yielded a
correlation coefficient (R2) of 0.9982. Error bars are displayed for each average normalized signal
as +/- 1 SD value (raw data shown in Figure 4.S1).

FBP Standard Curve under Class I Conditions
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Figure 4.8:
Standard curve for average normalized signal vs. FBP concentration over the range
of 0.1-500 μM.
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Based on the y-intercept for the calibration, it is evident that linearity breaks down at very
low FBP concentrations (< 1μM). Standard curve data from the low concentration values are
shown below in Figure 4.9. Error bars on these values correspond to %RSD in normalized signal
- ~90%, 33%, and 15%, respectively. These low concentrations, especially 0.1 μM, are
approaching the limit of detection for this method and thus signal varies widely scan-to-scan. For
example, of the three replicate analyses of 0.1 μM FBP, two gave average m/z 338.99 signal of 50
counts or less and one could not detect the ion at all. In the 0.5 μM and 1 μM samples, variability
decreases as the analyte concentration moves away from the limit of detection, but signal is still
low enough (<100 counts for 0.5 and <1000 for 1) for small variances in sample signal to have a
huge impact. Despite the high variability in FBP signal among these samples, their removal from
the data set did not affect the correlation coefficient and therefore they cannot be considered
outliers. Future analyses at low concentrations will require more replicates to counter the random
signal variability.
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Figure 4.9:
Linearity data for low concentration samples with error bars showing extreme
variability in signal intensity among triplicate analyses.
The high linear dynamic range when using this buffer demonstrates the importance of
keeping the concentrations of non-volatile buffer salts to a minimum for ESI-MS. Overall, linearity
experiments show promising results for analysis of in vitro aldolase reactions. It is important to
note however that the samples analyzed here did not contain enzyme and were not meant to
evaluate enzyme activity. Because the buffer salt concentrations used here were intentionally kept
significantly lower than those used for plate-based assays, additional experiments will need to be
conducted to ensure that the enzyme has catalytic activity. If any additional method development
is required, this would likely affect the linearity.

Precision
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Results of the six replicate repeatability trials are summarized in Table 4.3. The m/z of both the
substrate and internal standard extremely stable between runs, with standard deviations of 0.0002
m/z, which translates to %RSD values around 4e-5 %. The signal intensities exhibit some
variability run-to-run, but it is relatively low at <5%. The low run-to-run variability in signal
intensities is very promising, meaning that aliquots from a single enzymatic reaction can be
analyzed using one calibration which will save significant analysis time and materials.
Table 4.3:
Mean
SD
%RSD

Summary of repeatability experimental results.
13
FBP m/z
FBP Signal
C-FBP m/z
338.9980
503364
345.0183
0.0002
16739
0.0002
4.44e-5
3.33
4.36e-5

13

C-FBP Signal
113592
3612
3.18

The first studies of intermediate precision are based on variability on a single day between
different sample preparations (intraday intermediate precision, Table 4.4). As with the
repeatability experiment, there is almost no variation in m/z values between replicates and sample
preparations. On each of the two days, signal intensity %RSD is between 2-13%. While this is
relatively low, especially for day 2, intraday precision can easily be improved by re-running the
quantitation calibration solution between subsequent reaction experiments. At minimum,
recalibration should occur daily and when changing equipment because interday precision (Table
4.5) and precision between ESI spray needles (Table 4.6) are very poor. However, this is only the
case for signal intensity, which has %RSD ranging from 20-45%. On the other hand, although m/z
%RSD is one order of magnitude larger interday and between needles, it is still very low at 1-2e4 %.
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Table 4.4:

Intraday intermediate precision data for days 1 and 2.
Day 1
Day 2
Mean
SD
%RSD
Mean
FBP m/z
338.9964 5.00e-5
1.47e-5
338.9976
FBP signal
516753
63084
12.21
384734
13C-FBP m/z
345.0166 5.77e-5
1.67e-5
345.0179
13C-FBP signal
111584
10112
9.06
58403

Table 4.5:

Mean
SD
%RSD

%RSD
1.28e-4
2.88
1.26e-4
2.49

Interday intermediate precision between days 1 and 2.
FBP m/z
338.9970
0.0009
2.61e-4

Mean
SD
%RSD

Table 4.6:

SD
0.0004
11094
0.0004
1453

FBP signal
450744
93351
20.71

13C-FBP

m/z

345.0172
0.0009
2.60e-4

Variability data from analyses between spray needles.
13C-FBP m/z
FBP m/z
FBP signal
338.9972
315138
345.0175
0.0005
98425
0.0005
1.60e-4
31.23
1.50e-4

13C-FBP

signal

84993
37604
44.24

13C-FBP

signal

47965
14762
30.78

MSE

As an alternative to individual SRM experiments, full-scan fragmentation data was obtained
through MSE. Figures 4.10 and 4.11 below show the comparative scans between the low collision
energy (CE) state (7 eV) and the high CE (30 eV) state, respectively. In the low CE scan, signal
for the FBP and

13

C-FBP fragments are very low: about 2.5-2.6% of the signal for the intact

molecules. These 2.5-2.6% are likely due to the in-source fragmentation experienced by the ions
as they undergo the desolvation process by ESI and mass filtering before reaching the mass
analyzer. In-source fragmentation is especially relevant for phosphate-containing compounds, as
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the phosphate group is very labile and can dissociate as a highly stable phosphoric acid molecule.
When 30 eV of collision energy is used to disrupt stability of the ions, fragmentation is
significantly increased: 16.5-17% relative to the intact molecules.
In the MSE workflow, collision energy is constantly alternated between the high and low
state. Therefore, the data collected here represent data obtained from two distinct fragmentation
conditions within a single run for all ions in the range of 100-800 m/z. This is unique from the
classic multiple reaction monitoring (MRM) experiment which requires that ion pairs of interest
be selected and others be excluded from detection. In this case, with only two analytes of interest
with known fragmentation patterns, the MSE and MRM experiments are equally useful. However,
for untargeted studies or those studying a variety of compounds, MSE is a much simpler way to
obtain intact and fragmentation data in a single run. The downside is that the spectra can become
very difficult to interpret as more and more compounds are fragmented. By controlling the high
CE value, different fragmentation pathways can be accessed. For this study, 30 eV only resulted
in 16-17% analyte fragmentation by neutral loss of phosphoric acid. This allows identification of
unique fragments without decimating ion signal with destabilizing collision energies. As the
eventual goal of this study is to use HR-MS for both in vitro and in vivo enzymatic reaction
kinetics, MSE can be a very useful tool for identifying unknowns or quantitating various
compounds in the matrix.
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High CE (30 eV)

Proof of Method

The goal of this method is to analyze enzymatic reaction samples and obtain kinetic plots. To this
end, data from the reaction with 10 μM substrate are presented below. This data was obtained
using a discontinuous assay, the details of which are further described in the next chapter. In short,
aliquots are removed at various time points and quenched with acetonitrile and internal standard
before MS analysis. To save time and materials, quantitation is achieved with the use of a singlepoint response factor as opposed to a full standard curve.
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Figure 4.12: A concentration vs. time kinetic plot obtained using this HR-MS method with a
starting [FBP] of 10 μM, an enzyme concentration of 12.7 nM, and 10 μM [IS].

The plot shown above (Figure 4.12) with data obtained from the developed and validated
HR-MS method has the correct shape for an enzymatic reaction profile: a quick decrease in
substrate concentration as the transition from substrate to product happens, and equilibrium
eventually being reached and substrate concentration levelling out. This is evidence that rabbit
muscle aldolase has catalytic activity under the low-ionic strength conditions developed for this
method, and that the substrate turnover follows the typical profile seen for other aldolase assays.
Additionally, the concentration values (in the Appendix as Table 4.S2) calculated from the singlepoint response factor make sense based on the initial FBP concentration of 10 μM. These results
demonstrate the efficacy of this method for use as an aldolase assay.
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Conclusions

The data presented throughout this chapter show the development, validation, and use of a
high-resolution ESI-QqTOF-MS method for quantitation of fructose bisphosphate, the substrate
of the forward aldolase-catalyzed reaction. After MS parameters were optimized, the identities of
the substrate and internal standard were confirmed by exact mass to within 0.01 m/z and
fragmentation by both selected reaction monitoring (SRM) and mass spectrometry-elevated energy
(MSE). Neither the m/z for FBP nor the isotopically-labelled internal standard appeared in the
spectrum of the blank matrix sample containing buffer and aldolase enzyme, eliminating the
chance of isobaric ions in the matrix affecting quantitation. Linearity was established for FBP
concentration over four orders of magnitude, although increased signal variance was seen when
studying extremely low concentrations (< 1 μM). Based on precision experiments, quantitation
calibration should take place at least once daily to avoid errors in quantitation caused by signal
%RSD and as a best practice a new response factor will be determined prior to every reaction.
Method validation yielded very promising results, and a sample reaction was run to
evaluate catalytic activity of the enzyme under method conditions and the usefulness of the method
for FBP quantitation in the matrix. The experiment was able to confirm substrate turnover and the
quantitative ability of the QqTOF-MS. We believe that these results verify the high separative and
quantitative power of HR-MS, even without prior separation and/or clean-up by HPLC or SPE.
Future work will utilize the method developed and validated here to obtain kinetic parameters and
inhibition constants for the aldolase reaction in the hopes of providing a faster, less expensive, and
higher-throughput assay.
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CHAPTER 5
KINETIC ANALYSIS OF RABBIT MUSCLE ALDOLASE IN VITRO BY HR-MS

Introduction

As discussed previously, fructose bisphosphate aldolase is a strong target for drugs to treat
infectious diseases and human diseases such as cancer.120 To summarize, aldolase catalyzes the
reversible conversion of fructose bisphosphate to dihydroxyacetone phosphate and glyceraldehyde
3-phosphate in glycolysis and gluconeogenesis. Aldolases are divided into two categories (Class I
and Class II) based on their mechanism of action, with human aldolase falling into class I and
bacterial in class II. Therefore, most infectious disease treatments aim to target class II aldolases
exclusively. A notable exception is the malarial parasite Plasmodium falciparum which is known
to have class I aldolase.38 Therefore, class I aldolase is a potential target for future antimalarial
drugs. Additionally, many human cancer cells upregulate glycolysis enzymes to promote tumor
growth, making class I aldolase inhibitors a possible target for oncology drugs.120c, 121 The aldolase
tetramer from rabbit muscle is shown below in Figure 5.1.
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Figure 5.1:
PDB entry 6ALD showing the rabbit muscle aldolase tetramer with FBP bound to
each of the four active sites.

Class I aldolases are characterized by the formation of a Schiff base in the active site by
the carbonyl group on the substrate – either DHAP or FBP depending on the direction of the
reaction – and the amino group of a local lysine residue. This mechanism of action is quite different
from that of class II aldolase, which requires a divalent cation such as Zn 2+ in the active site to
interact with the carbonyl group on the substrate. Therefore, inhibitor design is highly dependent
on which type of aldolase is targeted. Phosphoglycolamide and phosphoglycolohydroxamic acid
are structural analogues of DHAP that act as inhibitors of class I aldolases.122 Both compounds
were shown to competitively inhibit rabbit muscle aldolase as well as the class II aldolase from
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Geobacillus stearothermophilus122 and Giardia lamblia92. Additionally, hexitol 1,6-bisphosphate,
which is similar in structure to fructose bisphosphate, also inhibits both class I and class II
aldolases.34, 37, 123
Many compounds can act as aldolase inhibitors including metals124, chelators125, synthetic
organic compounds34, 37, 126, and biological compounds127. For example, common physiological
compounds such as inorganic phosphate and adenosine nucleotides (AMP, ADP, and ATP) all act
as inhibitors of Trypanosoma brucei, rabbit muscle, and Staphylococcus aureus class I
aldolases.127a The mechanism and degree to which these compounds act as inhibitors varies. ATP
is a strong competitive aldolase inhibitor for all three species, with Ki values roughly between 0.31.3 mM. In general, as the net charge of the nucleotide decreases, its inhibition strength decreases
as well. Also, aldolase from S. aureus was generally less susceptible to inhibition by phosphates
and nucleotides. Other previous work37 has shown that hydroxynapthaldehyde phosphate
derivatives napthyl-2,6-bisphosphate (NA-P2) and 1,6-dihydroxy-2-napthaldehyde phosphate
(HNA-P) potently inhibit Schiff base formation in rabbit muscle aldolase. With fructose
bisphosphate as the substrate, NA-P2 competitively inhibited the aldolase reaction with a Ki of 0.28
+/- 0.03 μM, and HNA-P slowly binds to the aldolase active site and acts as a reversible inhibitor
with an estimated Ki of 24 +/- 5 nM. NA-P2 was also shown to inhibit aldolase from Trypanosoma
brucei – the causative agent of sleeping sickness. Further study showed that a similar
hydroxynapthaldehyde phosphate derivative called TBK1 could selectively inhibit parasitic class
I aldolases with little effect of rabbit muscle and human liver aldolases.34 After incubation with
100 μM TBK1 for 15 min, rabbit muscle and human liver aldolases retained 100% of their
activities whereas Plasmodium falciparum (malaria) and Leishmania mexicana (leishmaniasis)
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only retained 30% and 15% of activity, respectively. TBK1 appears to be primarily selective
toward T. brucei aldolase as it has <0.5% residual activity under these experimental conditions.
The ability f an inhibitor to selectively affect parasitic class I aldolases over mammalian aldolases
has important implications for safe and effective treatments for infectious diseases.
As discussed in Chapter 1, assays for fructose bisphosphate activity are usually plate-based,
multi-enzyme, and either colorimetric or fluorometric. Both the colorimetric and fluorometric
assays are indirect and discontinuous and colorimetric being utilized more often. The coupled
reaction scheme for colorimetric analysis of aldolase products is shown below in Chapter 1 in
Figure 1.7. As the aldolase-catalyzed reaction converts fructose bisphosphate (FBP) to
dihydroxyacetone phosphate (DHAP) and glyceraldehyde 3-phosphate (G3P), any G3P is
isomerized to DHAP by triose phosphate isomerase, and the DHAP aids in the conversion of
NADH to NAD+ by G3P dehydrogenase. This assay spectrophotometrically monitors the
absorbance of NADH in the UV at 340 nm. Therefore, as the aldolase reaction proceeds in the
forward direction, the observed signal from NADH absorbance would decrease over time.
The colorimetric assay is generally done in a continuous manner by directly analyzing the
reaction solution in a cuvette on a spectrophotometer during the initial reaction time. After the
signal from NADH absorbance is stoichiometrically converted to fructose bisphosphate
concentration, the plot of [FBP] vs. time will give the initial reaction velocity (V0). In order to
obtain a Michaelis-Menten curve, at least 7-10 different concentrations of FBP must be analyzed,
and often in duplicate or triplicate. The total reaction volume is often around 1.0 mL and contains
enzyme concentrations in the high nanomolar to low micromolar range and a variety of micromolar
to millimolar concentrations of substrate. Therefore, the material usage can really add up over time
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and, despite only dedicating a few minutes per sample, the assay throughput is severely hindered.
Large volumes or high concentrations are necessary for spectrophotometric determination because
of the low selectivity and sensitivity of the UV-Vis detector. Absorbance at 340 nm will detect
NADH as well as other components in the matrix that have an absorption maximum at or near that
wavelength. Because of this, matrix controls are crucial for getting accurate results, especially
when analyzing complicated matrices such as cell cultures – which will likely contain NADH from
other reactions. Additional complications from stray light, temperature or pH changes can also
negatively affect the precision and accuracy of spectrophotometric results. Finally, submicromolar concentrations of NADH challenge the sensitivity of the UV-Vis detector and can
negatively affect measurements. However, when high enough concentrations are used and matrix
interferences are accounted for, UV-Vis spectrophotometry provides reliable results on an
inexpensive and accessible detector. For these reasons, the colorimetric coupled-enzyme assay is
by far the most popular for kinetic analysis of the aldolase-catalyzed reaction.
To combat the poor sensitivity and selectivity of UV-Vis, fluorescence-based assays are
also available for aldolase. As seen in the illustrated schematic (Figure 5.2), this workflow is also
a coupled-enzyme assay, in this case added an extra step to activate a fluorescent probe through
NADH oxidation.39 A common fluorescent probe for this purpose is the reduction of resazurin –
which is a faint pink color in solution – to resorufin, a red fluorescent compound detected at 585
nm after excitation at 535 nm, the enzyme-catalyzed reaction for which is shown below in Figure
5.3.8b Fluorescence detection is much more sensitive than UV-Vis with detection limits often in
the picomolar range and in general fluorescence is less prone to matrix interference than UV-Vis
spectrophotometry. Therefore, the fluorescence assay requires very small sample volumes (< 100
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μL) and is done on microplates with detection on a plate reader. Microplates come in a variety of
sizes - including 96, 384, and 1536 wells – which allows for all reaction replicates and controls to
be done in one experiment on a single plate. The time and materials savings from using a single,
small volume plate for all experiments makes this assay extremely high-throughput, a powerful
advantage for inhibitor-screening applications. On the other hand, this assay can be costprohibitive because assay materials are often sold as expensive kits. In some cases, a 100-sample
reaction kit can cost $300-500128 and even without using a kit the fluorescent probe reagent is very
expensive.

Figure 5.2:
from: 39

Illustration of the fluorescent coupled-enzyme assay for aldolase. Reproduced
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Figure 5.3:
The enzyme-catalyzed conversion of resazurin to resorufin that is used as a
fluorescent probe because of the co-conversion from NADH to NAD+.

Mass spectrometry is a powerful separation tool both on its own and combined with another
separation technique such as LC or GC. While the majority of workflows utilize LC to account for
complicated sample matrices and provide a greater degree of separation, it is not always necessary
for in vitro kinetic studies. Excluding an LC gradient and instead relying on just MS significantly
improves analysis time, with MS spectra being collected over the course of seconds or a few
minutes. Additionally, mass spectrometry directly analyzes reaction components based on their
mass-to-charge ratio and does not require expensive labels for detection. Mass spectrometry also
provides a lot of variety in terms of the types of ionization sources and mass analyzers available.
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Electrospray ionization (ESI) is most often used for biological samples in the liquid phase,
but matrix-assisted laser desorption ionization (MALDI) can be used for samples on a solid
surface.129 It is important to note, however, that each ionization technique has its own specific
sample requirements for optimum detection. For example, ESI necessitates volatile buffer salts (or
pre-injection desalting if salt cannot be avoided) in order to prevent ion suppression, and MALDI
requires the sample to be combined with the matrix for desorption.46,
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Therefore, reaction

protocols are not always transferrable from spectroscopic or chromatographic assays to MS, and
some method optimization is usually required. Mass analyzers with high sensitivity, high linear
dynamic range, high mass accuracy, and MS/MS capability are preferred. Some examples include:
QqTOF, Orbitrap hybrids, and FT-ICR hybrids.117 All of these fall into the category of highresolution mass spectrometry (HR-MS), but low-resolution instruments such as ion traps are still
used for these applications.130
Several examples of assays for enzyme kinetics by MS exist and are categorized as either
continuous or discontinuous. In continuous assays, the reaction takes place in the syringe and a
small amount of the solution is constantly introduced into the mass spectrometer. A single run
tracks the substrate and product intensity vs. time and concentrations are determined by
comparison to signal from an internal standard. In discontinuous assays, on the other hand, the
reaction is run on the benchtop and small aliquots are removed, quenched, and analyzed by MS at
various time points. The majority of published MS assays for enzyme kinetics are discontinuous.
Kinetics and inhibition of hexokinase, the first enzyme in the glycolysis pathway, were
previously determined by an MS-only method.130 Similar to aldolase, hexokinase is usually studied
by coupled-enzyme spectrophotometric assays, and interferences by auxiliary enzymes and
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organic inhibitors cause discrepancies in measured kinetic parameters. This MS method can
directly assay reaction substrates and products by their mass-to-charge ratios, and quantitation
takes place through the use of an internal standard. In this case, 2-deoxy-glucose-6-phosphate was
used as an internal standard for the product glucose 6-phosphate, which is a less expensive but
somewhat less accurate alternative to using isotopically-labelled glucose 6-phosphate. In addition,
the kinetic parameters for the reaction were determined using a low-resolution ion trap mass
spectrometer, losing mass accuracy and resolving power but improving total assay cost. KM and
Vmax values were determined by analyzing reaction aliquots (quenched by methanol addition) over
time. The workflow for inhibitor library screening was different than the initial experiments:
hexokinase was immobilized on a gel, incubated with substrates and inhibitors for a few minutes,
and washed prior to ESI-MS analysis on a high-resolution FT-ICR mass spectrometer. Mass
spectra were taken before and after inhibitor incubation and were compared to show the presence
or absence of reaction biomarkers. In this inhibition study, a variety of potential inhibitors were
screened quickly and those showing inhibitory activity were studied further to obtain Ki values.
HR-MS was chosen for this study because the analyte ions could be identified with high accuracy.
Using this fast and accurate workflow, 10/12 compounds in a mock library were identified as
potential hexokinase inhibitors based on differences in mass spectra.130
The case of phosphoglucomutase, the enzyme that catalyzes the reversible isomeric
conversion of glucose 1-phosphate (G1P) to glucose 6-phosphate (G6P), presents a unique
difficulty for direct MS detection because the substrate and product ions have the same exact mass.
As a way to circumvent this issue, ion-molecule reactions (IMR) using the mass spectrometer as a
reaction vessel provide an indirect method of identification. In this case, the neutral compound
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trimethylborate (TMB), which is known to react with the phosphate groups of phosphorylated
compounds, was introduced into the ICR cell of the ESI-FT-ICR instrument. Based on the position
of the phosphate group, G1P and G6P yielded unique product ion distributions. Each product was
assigned a diagnostic ion and the relative intensities of those ions were used for quantitation. As
the enzymatic reaction proceeded, aliquots were removed and quenched with three volumes of
acetonitrile, making this a discontinuous assay. Due to the reaction buffer containing Mg2+ the
samples were desalted a strong-cation exchange resin prior to MS, helping to reduce ion
suppression in negative ion mode. Performing reactions with varying concentrations of substrate
and in both directions allowed this workflow to be used to determine KM values for two different
substrates of phosphoglucomutase, Vmax values for both directions of the G1P to G6P conversion,
and the equilibrium constant (Kd) for the enzyme-substrate interaction.131
As part of their work on MEP pathway enzymes and inhibitors, Narayanasamy et al.
confirmed IspF activity by TOF-MS.28 For this workflow, the in vitro reaction was run under
biological conditions with MOPS buffer and 5 mM MgCl2 and quenched with EDTA after 30 min.
As the reaction conditions were not suitable for ESI, the solution was completely dried and
redissolved in 1:1 MeOH: H2O prior to MS analysis. The TOF-MS monitored the conversion of
the substrate CDP-ME2P to MEcPP based on m/z in the negative ion mode. The assay was not
quantitative in this case, but instead was used to confirm enzyme activity as a supplement to
radiometric and spectrophotometric methods.
The aim of this study is to use HR-MS to obtain kinetic data for class I fructose
bisphosphate aldolase from rabbit muscle without the use of HPLC. Methods for both continuous
and discontinuous reaction monitoring are described and results from both workflows are
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compared. Additionally, known aldolase inhibitors adenosine monophosphate (AMP) and
adenosine triphosphate (ATP) were evaluated as part of the proof-of-concept.127a

Materials and Methods

Chemicals

D-fructose 1,6-bisphosphate trisodium salt octahydrate (98%), ammonium acetate, sodium
chloride, and acetonitrile (HPLC grade) were purchased from Fisher (Chicago, IL). Aldolase from
rabbit muscle, adenosine 5’-monophosphate (AMP, >99%), and adenosine 5’-triphosphate (ATP,
disodium salt hydrate, 99%) were purchased from Sigma (St. Louis, MO). (13C)6-D-fructose
bisphosphate sodium salt hydrate (98%) was purchased from Cambridge Isotope Laboratories Inc.
(Andover, MA). All water used in experiments was filtered with an in-house Milli-Q 18MΩ.cm
R-O system (EMD Millipore, Billerica, MA).

Instrument Parameters

Samples were analyzed on Bruker MaXis Plus ESI-QqTOF in the negative ion mode between 100800 m/z. Sample was delivered by KD Scientific model 100 syringe pump (KD Scientific Inc.,
Holliston, MA) at a rate of 200 μL/hr. For the discontinuous assay, the ESI source parameters were
as follows: 210 °C dry gas temperature, 8.0 L/min dry gas (N2) flow, 1.6 bar nebulizer gas (N2)
pressure, 4.0 kV capillary voltage, and 500V end plate offset. The QqTOF-MS was tuned as
follows: funnel RF 300 Vpp, multipole RF 200 Vpp, collision RF 1000.0 Vpp, ion cooler RF 800
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Vpp, isCID 0.0 eV, ion energy 4.0 eV, collision energy 7.0 eV, pre-pulse storage 5.0 μs, transfer
time 50.0 μs. Some tune parameters were modified for the continuous assay: 150 °C dry gas
temperature, 2.5 bar nebulizer gas pressure, 3.5 kV capillary voltage, and 1200 V end plate offset
for the source.

Response Factor for Quantitation

Prior to analyzing samples from reactions, a solution of equal concentration of substrate and
internal standard was run. From this solution a response factor (F) was calculated using the below
equation, and the response factor was used for quantitation of reaction samples. This equation was
then rearranged in order to calculate the concentration of FBP for each sample.

𝑅=

𝐼𝐼𝑆 ∗ [𝐴]
[𝐼𝑆] ∗ 𝐼𝐴

[𝐴] =

[𝐼𝑆]𝐼𝐴 𝑅
𝐼𝐼𝑆

IIS and IA are intensities of internal standard and analyte, respectively
[IS] and [A] are concentrations of internal standard and analyte, respectively

Equation 5.1: (top) the equation used to calculate response factor and (bottom) the rearranged
equation used to calculate FBP concentration

Discontinuous Assay

In vitro aldolase reaction: 12.7 nM aldolase tetramer from rabbit muscle was incubated at room
temperature in reaction buffer (10 mM ammonium acetate pH 7.5 with 2 mM NaCl) and the
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enzymatic reaction was initiated by addition of varying concentrations (2-50 μM) FBP, and the
final reaction volume was 1.0 mL. At various time points, 100 μL aliquots of reaction solution
were removed and 125 μL acetonitrile was added to quench the reaction. Samples were stored in
the freezer until the time of analysis, at which point 6-13C FBP was added to a final concentration
of 10 μM and reaction buffer was added to a final sample volume of 250 μL. Each aliquot was
analyzed by ESI-MS in negative ion mode and the concentration of FBP was calculated from the
response factor. Reaction progress was plotted as concentration of FBP vs. time, and initial
velocity (Vi) was calculated from the reaction curve. A Michaelis-Menten plot was generated
based on the range of initial concentrations of FBP. From that curve and its double-reciprocal plot,
kinetic parameters KM, Vmax, kcat, and turnover number were calculated.

𝑘𝑐𝑎𝑡 =

𝑣𝑚𝑎𝑥
[𝐸]

Equation 5.2: The equation for catalytic rate (kcat)

𝑡𝑢𝑟𝑛𝑜𝑣𝑒𝑟 𝑛𝑢𝑚𝑏𝑒𝑟 =

𝑘𝑐𝑎𝑡
𝐾𝑚

Equation 5.3: The equation for turnover number used for comparison of different inhibitors

99

Continuous Assay

Figure 5.4:

A schematic showing the reaction set-up for the continuous enzyme assay.

In syringe pump 1, 12.7 nM aldolase tetramer and varying concentrations of FBP were combined
in reaction buffer and delivered to ESI source at 200 μL/hr. Syringe pump 2 delivered 10 μM 13CFBP (the IS) at the same flow rate. The schematic for the reaction set-up is shown in Figure 5.4.
The lines from the two syringe pumps were connected by a mixing tee prior to entering the ESI
source. From the time the enzymatic reaction was started by addition of FBP, the MS monitored
the signal from m/z 338.99 (FBP) and 345.01 (IS). The reaction was allowed to proceed for roughly
10 min while extracted ion chromatograms (EIC) monitored the signal of substrate and internal
standard over time. The intensities of these two ions and the calculated response factor were used
to determine the concentration of FBP over time, and from that curve the initial velocity was
obtained. A plot of Vi vs. initial [FBP] yielded Vmax and KM values.

100

Results

Discontinuous Assay with No Inhibitor

Below is a sample reaction profile from the 10 μM initial substrate reaction (Figure 5.5) and the
calculation of initial rate (Vi) based on the first few data points of the reaction (Figure 5.6).
Additional reaction profiles and initial rate graphs are presented in the Appendix C. The shape of
the reaction profile is prototypical of a forward reaction monitoring decreasing substrate
concentration: a sharp decrease in the beginning of the reaction time followed by a levelling of
concentration as the reaction reaches equilibrium. The data points in the sharp decrease (0-2 min)
were used to calculate the initial rate of 2.7985 μM/min. The linearity is very high over this stretch
of time with a correlation coefficient of 0.9759. This process was repeated for various
concentrations between 2-50 μM FBP, with only the first 5-7 min of the reaction analyzed in order
to save time and materials. Because the reaction reaches equilibrium faster at higher substrate
concentrations, the number and identity of time points used for initial rate calculations and the
strength of linear fit varies slightly.
While most reactions proceeded in a typical manner, there were some issues with reaction
monitoring and quantitation at low and high substrate concentrations, albeit for different reasons.
When investigating precision for this HR-MS method in the last chapter, high variability in signal
intensity and quantitation was reported at concentrations at or below 1 μM FBP. Figure 5.7
demonstrates the extreme discrepancy in reaction curves obtained from duplicate reactions with 1
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Figure 5.5:
inhibitor.

A sample reaction profile for the aldolase starting with 10 μM FBP and no added
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Figure 5.6:
The first few time points representing the initial reaction from Figure 5.5, and the
linear fit to yield the initial reaction rate of 2.7985 μM/min.
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μM initial FBP concentration. The calculated initial reaction rate from Trial 2 is more than double
that of Trial 1, and because of continued variability in quantitation from these low concentrations,
2 μM was the lowest condition tested. On the other hand, as shown in Figure 5.8, reaction profile
from 50 μM initial FBP concentrations does not show the usual exponential decrease in substrate
concentration. It is widely known that as initial substrate concentration increases, initial reaction
rate also increases. Therefore, the reaction reaches equilibrium very quickly after the addition of
the substrate to trigger the start of reaction; and when the assay is run in a discontinuous manner
with only a finite number of time points, those data points may not fully represent the initial
reaction phase. In those cases, the first few time points (0-0.5 min) were used indiscriminately for
Vi calculation. The linear correlation is much poorer than those of lower concentrations, but the
data obtained by this approach appear to fit the Michaelis-Menten model nonetheless.
The Michaelis-Menten and Lineweaver-Burk plots obtained by analyzing seven
concentrations of FBP in the absence of inhibitor are shown below in Figures 5.9 and 5.10. Both
plots confirm that the Michaelis-Menten model is appropriate for determining reaction kinetics for
rabbit muscle aldolase. In other words, the Michaelis-Menten plot is hyperbolic and the doublereciprocal (Lineweaver-Burk) plot is linear, showing a lack of allosteric binding that would cause
a sigmoid-shaped plot and the inability to determine kinetic data with this model. Kinetic
parameters extracted from this data are listed in Table 5.1.
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Figure 5.7:
Reaction profiles from two trials of reaction with 1 μM initial FBP concentration.
Both the shapes of the curves and the calculated initial rates are markedly different from each
other.
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Figure 5.8:
Reaction profile from the 50 μM initial FBP concentration reaction. There is no
sharp decrease in substrate concentration indicative the initial rate phase, so the first three data
points were used to calculate initial rate.
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Figure 5.9:
The calculated Michaelis-Menten curve obtained from the initial rates of reactions
ranging from 0-50 μM FBP in the absence of inhibitor.
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Figure 5.10: The double reciprocal plot with a linear fit used to determine the Michaelis constant
and maximum reaction rate.
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Table 5.1: Summary of kinetic parameters obtained for rabbit muscle aldolase without inhibitor.
Kinetic Parameters for Rm
aldolase without Inhibitor
38.3
KM (μM)
2.10e-1
Vmax (μM/s)
kcat (s-1)
4.13
-1 -1
kcat/KM (M s )
1.08e5
1 μM AMP as an Inhibitor

Experiments with the same initial concentrations of FBP were repeated with the addition of 1 μM
AMP, a known inhibitor of rabbit muscle aldolase. Figures 5.11 and 5.12 show the new MichaelisMenten and Lineweaver-Burk plots, respectively. The hyperbolic shape of the Michaelis-Menten
curve is less obvious with AMP, but there is still no evidence of allosteric binding. Table 5.2 lists
the new kinetic parameters for the inhibited enzyme. As with the uninhibited reactions, the
individual reaction profiles and initial rate calculations are listed in the Appendix. It is important
to note that in this case only the first 5-7 minutes of the reactions were measured for FBP
concentration in an effort to save time and materials.
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Michaelis-Menten with 1 μM AMP
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Figure 5.11:

The Michaelis-Menten plot produced from reactions with 1 μM AMP.

Lineweaver-Burk with 1 μM AMP
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Figure 5.12:

The Lineweaver-Burk plot with the linear fit.
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Table 5.2: Summary of kinetic parameters for aldolase with 1 μM AMP.
Kinetic Parameters for Rm
aldolase with 1 μM AMP
Inhibitor
32.7
KM (μM)
6.6e-2
Vmax (μM/s)
kcat (s-1)
1.30
-1 -1
kcat/KM (M s )
3.98e4

1 μM ATP as an Inhibitor

Reactions were again repeated, this time with another known nucleotide inhibitor, ATP. In this
case, there were issues with quantitation of the 25 μM sample because the signal for FBP and IS
are approximately equal and role of scan-to-scan signal variability was exacerbated in the
averaging process (Figure 5.13). Because of this, data from a 100 μM reaction was added to keep
the number of data points constant throughout all three analyses. In spite of issues with 100 μM
reaction quantitation problems under uninhibited conditions, with ATP present the reaction is
slowed enough that the initial rate can be elucidated. Figures 5.14 and 5.15 show the kinetic plots
obtained from experiments with ATP, and the calculated kinetic parameters are listed in Table 5.3.
Again, there is no evidence of allosteric binding with ATP, but the Lineweaver-Burk plot presents
some error in linear fit primarily due to mid-range FBP concentration data points. This contributes
to the overall method error, although the correlation coefficient is still relatively high at 0.9585.
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Figure 5.13: The extracted ion chromatogram showing signal for FBP (blue) and IS (orange) for
the 25 μM initial [FBP] after 2 min incubation time.
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Figure 5.14:

The Michaelis-Menten plot for aldolase with 1 μM ATP.
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Lineweaver-Burk with 1 μM ATP
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The double reciprocal plot with linear fit for aldolase in the presence of ATP.

Table 5.3:
The summary of kinetic parameters for aldolase with 1 μM ATP.
Kinetic Parameters for Rm
aldolase with 1 μM ATP
Inhibitor
145.6
KM (μM)
7.71e-2
Vmax (μM/s)
kcat (s-1)
1.52
-1 -1
kcat/KM (M s )
1.04e4
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Discussion

Kinetic Parameters for Rabbit Muscle Aldolase by a Discontinuous Assay

Based on the data presented above, analysis of reaction aliquots with QqTOF-MS is a viable
discontinuous assay for studying aldolase activity in vitro. The method was able to effectively
monitor aldolase reactions and obtain kinetic parameters using the Michaelis-Menten model. Table
5.4 samples KM values determined for rabbit muscle aldolase in the absence of inhibitor using the
typical colorimetric or fluorometric coupled-enzyme assays. The literature values range from
approximately 2-20x lower than the one obtained using this HR-MS method. The most likely
explanation for the decrease in catalytic activity is the low ionic strength in solution for this method
compared to those in the literature, and previous studies have confirmed that aldolase activity is
inversely proportional to ionic strength (I) at I <0.1M.127a, 132 In this case, the ionic strength was
intentionally kept lower than the typical assay conditions in order to be better suited for ESI-MS.
Specifically, the buffer was changed from the usual TEA-HCl to ammonium acetate for more
efficient electrospray and the concentration was reduced to 10 mM from the typical 50-100 mM.
In addition, the 2 mM NaCl used for this study represents a dramatic reduction from the 50 mM
often used and the chelator EDTA was eliminated from the assay protocol altogether. In spite of
these changes to the reaction conditions, aldolase still remained active and the KM was generally
on the same order of magnitude as the literature values.
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Table 5.4:
Examples of KM values for rabbit muscle aldolase in the literature obtained using
the colorimetric or fluorometric coupled-enzyme assay.
KM (μM)
2
20

12.8
13

9.5
5.1
15

Comment
Reference
133
Colorimetric coupled enzyme assay
134
Colorimetric coupled enzyme assay
0.1 M glycyl-glycine buffer pH 7.4 with 0.2 M
KOAc
127a
Colorimetric coupled enzyme assay
50 mM TEA-HCl pH 7.6; I = 0.1 M
37
Colorimetric coupled enzyme assay
100 mM TEA-HCl pH 7.6 with 50 mM NaCl; I =
0.15M
135
Colorimetric coupled enzyme assay, 30 °C
50 mM TEA-HCl pH 7.4
136
Colorimetric coupled enzyme assay
91a
Colorimetric coupled enzyme assay
0.1 M glycyl-glycine buffer pH 7.4 with 0.2 M
KOAc

In the presence of inhibitors AMP and ATP, the data show a decrease in reaction rate and
other kinetic parameters – demonstrated visually in the overlay of the three Michaelis-Menten
plots in Figure 5.16 and listed in Table 5.5. As AMP and ATP are known to inhibit rabbit muscle
aldolase, this is not a surprising result but does allow for confirmation that our HR-MS method is
able to detect enzyme inhibition. Figure 5.16 shows that the overall Vmax of the reaction is lowered
when incubated with either 1 μM of AMP or ATP. Based on comparison of the turnover numbers
(kcat/KM), rabbit muscle aldolase activity is roughly 2.7x lower in the presence of AMP and about
10.4x lower with ATP. AMP appears to be a non-competitive inhibitor of rabbit muscle aldolase
based on the difference Vmax value, but very similar KM value, 32.7 μM, compared to 38.3 μM for
the uninhibited reaction. This is in opposition to a study in the literature which identifies it as a
competitive inhibitor.127a For an inhibitor to be competitive based on the Michaelis-Menten model,
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the Vmax in the presence of an inhibitor would be approximately the same than that of the
uninhibited one and the KM values would vary. In the same study, ATP is also listed as a
competitive inhibitor.127a However, our data show the inhibition as mixed, with both KM and Vmax
being different from the parameters for the uninhibited reaction. Future work will include more
replicates of these experiments and more reactions with varying concentrations of inhibitors to be
more certain about the exact degree and mechanism of inhibition.

Comparison of Michaelis-Menten Curves
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Figure 5.16: An overlaid chart of the Michaelis-Menten curves with no inhibitor (blue), AMP
(orange), and ATP (gray).
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Table 5.5:

Summary of the kinetic parameters for all three aldolase conditions.

KM (μM)
Vmax (μM/s)
kcat (s-1)
kcat/KM (M-1s-1)

No Inhibitor
38.3
2.10e-1
4.13
1.05e5

1 μM AMP
32.7
6.60e-2
1.30
3.98e4

1 μM ATP
145.6
7.71e-2
1.52
1.04e4

Assay Viability

As mentioned previously, each of the reactions were only run for 5-7 minutes to save time and
materials. This dramatically increased speed, but full reaction curves were not obtained.
Additionally, the analysis time per sample was very low: 1-2 min of data collection followed by
several minutes of instrument rinse. This is comparable to that of the spectrophotometric assay,
and for HR-MS no incubation time was required from reaction to quenching to analysis (as is often
the case with coupled enzyme assays). The total time required to run and analyze the one reaction
was about 1 hr using this method, and a single Michaelis-Menten curve could be obtained in 7-8
hrs. At this point, the run time of this assay significantly hinders the throughput compared to a
plate-based assay in which all reactions and replicates can be performed on a single microplate.
However, unlike colorimetric and fluorometric assays, this method is a direct analysis of fructose
bisphosphate and does not require auxiliary compounds for detection, significantly simplifying the
sample matrix and subsequently the analysis process.
Not only is the method direct, but it is very specific. Only the [M-H]- ions for FBP and the
IS +/- 0.01 m/z are taken into account, decreasing the overall matrix interference. For example,
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several samples contained a peak at m/z 339.20 – very close to that of FBP at m/z 338.99. Without
the specificity provided by the exact mass measurements, this peak may have been incorrectly
applied to the quantitation of FBP and could have severely impacted the accuracy of kinetic data.
Moreover, the specificity and sensitivity of HR-MS is much higher compared to colorimetric
assays, which are especially susceptible to background interference. In addition, any matrix
interferences to quantitation are taken into account in HR-MS during the quantitation calibration
process with the isotopically-labelled internal standard. In other words, since FBP and its
isotopically-labelled counterpart have identical ionization efficiencies and are affected equally by
adduction, in-source fragmentation and other forms of ion suppression, recalculation of the sample
response factor prior to each reaction analysis increases precision and accuracy by taking small
run-to-run changes in ionization and signal into account.
Important to note is that the specificity and sensitivity provided by MS is achieved without
analyte tags or derivatization, although quantitation requires an isotopically-labelled IS. This
provides a significant improvement over assays requiring fluorescent or colorimetric tags and/or
probes in other assays. However, as aldolase will also turn over (13C)6-FBP, it is vital that the IS
is added after reaction quenching and immediately before sample analysis to keep signal consistent
throughout the run and ensure accurate quantitation.
Despite the many advantages provided by using HR-MS over traditional assays for aldolase
activity, method development for this application is still in its early stages and is not without issues.
One issue that was noted in this study is with the quantitation of FBP at concentrations greater
than or equal to 50 μM. As a possible solution, reactions with an initial FBP concentration above
50 μM were tried with a response factor solution of 50 μM each of FBP and the IS, but that did
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not make a difference and the issue seems to be unrelated to the quantitation calibration. It is more
likely that the reaction rate is very high at high concentrations of FBP such that the few time points
analyzed below 30 sec reaction time are not enough to accurately calculate the initial rate.
Another drawback of the assay in its discontinuous form is the amount of benchtop labor
required for MS analysis. The multitude of pipetting steps needed for preparation of stock
solutions, reactions solutions, and quenched aliquots each comes with random error and to the total
error of the assay. However, the same can be said of traditional aldolase assays, with the exception
of those that utilize automatic pipetting systems. In addition to labor, the discontinuous method
also requires consumables (sample tubes, pipet tips, etc.), the waste and cost of which can add up
over time. However, there is room for improvement in terms of material use. As this study
represents the early stages of method confirmation, the 1.0 mL total reaction volume and 250 μL
sample volume were purposefully kept higher than necessary. In reality, at 200 μL/hr and 1-2 min
per sample, the required sample volume is extremely low. Theoretically, sample volumes could be
cut 5-10-fold, although this would require a much smaller sample syringe than the 500 μL one
used here and possibly a special low-volume syringe pump.
The largest cost barrier for this method is obviously the high-resolution instrumentation,
which is generally in the hundreds of thousands of dollars. But as more and more labs acquire HRMS instrumentation, their use can be expanded to include enzyme kinetics. Besides the internal
standard (~$250-500/50mg), the operational cost of this assay is relatively inexpensive. This is a
significant improvement for fluorescent assays in particular because fluorescent tags are often very
costly.
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The biggest issue with using ESI-MS is the stringent sample requirements, specifically
with respect to non-volatile salts. As discussed above, the low enzyme turnover rate compared to
literature values is likely a symptom of the low ionic strength of the reaction buffer. For additional
experiments in which the ionic strength is raised and/or a more complicated sample matrix (e.g.
cell lysate for in vivo studies) is analyzed, a sample clean-up technique such as filtration or solid
phase extraction (SPE) will be needed. SPE is a relatively fast, simple, inexpensive, and effective
process with a variety of resins available commercially depending on the application. In this case,
widely available desalting or anion-exchange cartridges would be optimal. SPE clean-up is usually
achieved in a few minutes, saving significant time compared to HPLC. Therefore, a wider variety
of samples could be analyzed with optimum aldolase activity without compromising specificity
and sensitivity and while keeping operational cost relatively low.

Continuous Assay

Attempts to elucidate kinetic parameters for aldolase via a continuous assay were much less
successful than the discontinuous assay. Figure 5.17 below shows a full 45 min reaction with 5
μM initial FBP concentration and extracted ion chromatograms for FBP (green) and the IS (purple)
monitored continuously. This chromatogram indicates a forward-proceeding reaction based on the
decrease in FBP signal in the first several minutes. After roughly 5 minutes of reaction time, the
signal for FBP stays roughly the same for the rest of the run time. Based on this, subsequent
reactions were only analyzed for about 10 min to save time. As described in the assay protocol,
the internal standard solution is pumped into the MS using a separate syringe from the enzyme and
substrate mixture. This is due to the fact that the enzyme does not discriminate between native
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FBP and isotopically-labelled FBP. It is clear from the stability of signal in purple trace that the
enzyme is not affecting the internal standard during their brief mixing period before entering the
MS. This ensures that quantitation is true to the actually concentration of the IS and quantitation
error is not due to modifications in IS concentration caused by the enzyme.

Figure 5.17: Chromatogram trace of signal from FBP (green) and the IS (purple) for the
continuous reaction with 5 μM initial [FBP].

Although the chromatogram shows that the enzyme-substrate reaction is occurring,
precision for this assay is very low. Figure 5.18 shows data extracted from duplicate analyses of 5
μM FBP reactions on the same day. In general, both trials show the decrease in FBP concentration
over the first several minutes of the reaction. However, when initial rates are calculated, the two
rates of 1.8161 and 2.6090 μM/min, respectively, demonstrate a 43% difference. This significantly
hinders assay robustness and throughput as it is likely that many trials of each reaction will need
to be done to get a precise and accurate result.
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Figure 5.18: Overlay of quantitation data extracted from duplicate trials of 5 μM continuous
reactions. The slight differences in curve shapes translate to a 43% difference in calculated reaction
rates.

In addition, not all continuously-monitored reactions demonstrate the decrease in FBP
signal over time. One example is Figure 5.19, which shows the chromatogram for the reaction with
100 μM initial FBP concentration. In this case, there is no characteristic drop in FBP signal and it
appears that the reaction has already reached equilibrium by the time data collection started. In
another more bizarre example (Figure 5.20), the FBP signal (blue trace) from the 10 μM initial
concentration reaction appears to stay constant up until 25 min reaction time before steadily
increasing over the final 20 min of the run. This is particularly odd because the IS signal (orange)
stays fairly constant throughout the whole time and does not increase along with FBP in the last
20 min.
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Figure 5.19: Extracted ion chromatograms from FBP (purple) and the IS (green) from a
continuous reaction with 100 μM aldolase.

Figure 5.20: Continuous reaction analysis starting with 10 μM FBP monitoring signal from FBP
(blue) and the IS (orange).

Both Figures 5.19 and 5.20 represent instances in which no useful kinetic data could be
obtained from runs with the continuous HR-MS assay. Alongside the issues mentioned above with
run-to-run precision, this invalidates the usefulness of this assay in its current form. In order for
this assay to be successful in the future, several aspects of the protocol will need to be optimized.
One important example is the offset between the time that the reaction is begun (i.e. when the
substrate is added to the enzyme) and when MS data collection begins. The offset time is generally
between 20-30 s, which is not necessarily a significant issue at low concentration reactions (e.g.
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the 5 μM one in Figure 5.17) but makes a huge difference at higher concentrations when the
reaction rate is increased. This explains the appearance of the 100 μM FBP reaction chromatogram
in Figure 5.19; the non-equilibrium reaction could be occurring during the first 30 s and therefore
missed because of the initial set-up time. Therefore, the procedure must be optimized in the future
before any useful data can hope to be attained from higher concentration substrate reactions.
Moreover, issues with precision must be resolved in order to make this continuous viable. Several
factors can contribute to an overall lack of precision, including signal variability and incorrect or
incomplete mixing. As shown in the chromatograms above, ion signal constantly varies scan-toscan in a random manner and only about 10-20 scans are averaged per time point. The low scan
number indicates the importance of each of the individual scans in the averaging process, and even
small variations in a few scans can make a significant difference in quantitative data. Future work
will take advantage of the high scan speed of the QqTOF to allow for more scans to be taken per
time, hopefully dissipating the amount of random variation in intensity. In addition, as shown
above in Figure 5.4, the current assay procedure combines solutions from two syringes via a
mixing tee before entering the ESI source. The mixing apparatus used here is Y-shaped and mixing
dead volume of 1.7 μL. The degree of mixing in the tee has a profound effect on sample
consistency and the relative signal intensity between the analyte and internal standard, and a lack
of appropriate mixing is another possible cause of the lack of precision for this method. Significant
future effort will be directed toward optimizing the mixing process, including modifying syringe
pump flow rate and trying different varieties of mixing apparatuses, to obtain the best possible
results.
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Conclusions

The work presented here conclusively demonstrated that a discontinuous HR-MS method
using QqTOF-MS without chromatography or sample clean-up can detect and quantitate rabbit
muscle aldolase activity with and without inhibitors. Results showed that kinetic parameters for
enzyme activity can be elucidated using the Michaelis-Menten model. However, the KM values
from this study are slightly higher than those in the literature, likely due to the low ionic strength
of the reaction buffer. In addition, both AMP and ATP were confirmed to inhibit aldolase at 1 μM,
albeit not in a competitive manner as reported in the literature. On the other hand, the continuous
assay protocol was not shown to be viable because of issues with timing and precision.
The goal of this research is to provide improvements in sensitivity, specificity, and
throughput of current aldolase assays to facilitate inhibitor screening. The exact mass
measurements from QqTOF-MS significantly increase specificity and sensitivity, especially with
regard to the spectrophotometric assay that is most common for this application. Additionally, the
method presented here eliminates the use of auxiliary enzymes and fluorescent probes, simplifying
the assay protocol compared to coupled-enzyme assays. Also, while the upfront cost for the MS is
very high, the operational cost of the assay is fairly low and conditions can be optimized to save
materials.
The largest disadvantage at this point in using the discontinuous MS assay is the amount
of benchtop labor needed to run and quench reactions. By working to make the continuous assay
a consistently-viable option, the directness, sensitivity, and specificity of the discontinuous assay
can be combined with the speed and ease of the continuous assay protocol to produce a truly highthroughput alternative to colorimetric and fluorometric assays.
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CHAPTER 6
CONCLUSIONS AND FUTURE WORK

The aim of this work was to develop effective chromatography and mass spectrometry
methods for use in quantitation of enzyme activity and inhibition. To this end, Chapter 3 described
a short, isocratic HILIC HPLC method for nucleotides in the MEP pathway. The FructoShell-N
column demonstrated high separation efficiency and the run time could be varied by changing the
flow rate. Additionally, preliminary data showed that the method is MS-applicable and could be
transferred to aldolase with no changes. In the future, this method can be utilized for UV-active
MEP pathway analytes not requiring MS, such as ADP and ATP in the IspE reaction. However,
the HILIC method alone has limited applicability because other reactions like aldolase do not have
UV-active substrates and products. But unlike some other methods for phosphates, this method is
easily MS-applicable and future work will focus on optimizing LC-MS conditions for activity,
inhibition, and biomarker assays by analyzing real samples containing MEP pathway substrates,
enzymes, and buffers.
In Chapters 4 and 5, MS – specifically HR-MS – methods were used to fill the gap left by
insensitive and non-specific UV detection. The HR-MS method developed in Chapter 4 is fast,
specific, sensitive, uses very little materials, and has high precision and accuracy for experiments
completed with FBP and its isotopically-labelled internal standard. This method could also be
applied to other phosphate-containing compounds such as those in the MEP pathway with little-
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to-no changes to instrument parameters. It should also be noted that the HR-MS method developed
in this chapter, as well as the LC methods from Chapter 3, directly detect phosphate-containing
compounds in their native state without the need for time-consuming derivatization processes. We
believe that makes for an easier, faster, and cheaper assay compared to those needing analyte
derivatization or tagging.
In Chapter 5, the HR-MS method was applied for kinetic studies of rabbit muscle aldolase
successfully un-inhibited and in the presence of two known inhibitors, although there is still work
to be done for optimizing parameters. Under the current protocol, the reaction is run on the
benchtop, aliquots are removed and quenched, and the concentration of FBP is determined by HRMS. This method represents a significant improvement in specificity compared to other methods,
but improvements in benchtop labor need to be made in order for the assay to be high-throughput.
To this end, a continuous assay was developed and applied with mixed results. Specifically,
precision and robustness are substantial problems. As shown in Chapter 5, there are large run-torun differences in experimental Vi values and even the shape of reaction curve. One possibility for
this is insufficient mixing of the solutions from the two syringe pumps in the tee. In the future, the
precision issues with this assay will be addressed by optimizing sample mixing prior to entering
the ESI-MS. For example, as opposed to a simple mixing tee, turbulent mixing can be deterred and
mixing efficiency can be optimized by using a channeled microfluidic device.137 To discourage
parallel flow within the channels, agitation of the system may also be required.138
Perhaps the most prolific issue with studying biological systems using ESI-MS is signal
suppression caused by non-volatile buffer salts. In the ESI-MS experiments described in this
dissertation, salt concentrations were intentionally kept low to ensure acceptable and reproducible
signal. However, it was hypothesized in Chapter 5 that the low buffer strength contributed to lower
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binding affinity between the aldolase and fructose bisphosphate, thus skewing the accuracy of
kinetic parameters. Therefore, in order to obtain kinetic results that can be compared to literature
values and to truly gauge the effectiveness of the method, ionic strength must be comparable to
experiments described in the literature. However, recent experiments have revealed that significant
ion suppression leading to imprecise quantitation is seen with even a small increase in NaCl
concentration from 2 mM to 5 mM (data not shown). To reach the necessary concentrations of 50100 mM NaCl, HR-MS will need to be combined with a separation method for pre-ESI desalting.
Optimally, this would be the HILIC UPLC method developed as part of Chapter 3, which was
shown to separate nucletotides and retain FBP and to be ESI-MS-compatible. The current runtime
for HILIC is about 10 min per sample and offers an on-line and automated separation, desalting,
and quantitation method by LC-MS. Another option is off-line desalting by solid-phase extraction
(SPE), completed using single-use cartridges on the benchtop in under 5 min per sample. This
technique will not separate analytes from each other in a mixture like HPLC, but act as a sample
preparation technique and separate matrix components from analytes. Both of these avenues will
be explored as a means of studying enzyme kinetics under realistic biological conditions. Ideally,
the assay would abandon the discontinuous method of sampling and instead be able to study
reactions by microfluidic mixing followed by an on-line quenching, desalting, and
detection/quantitation protocol.
After optimization, the methods developed here – LC, LC-MS, and HR-MS – will be
applied to in vitro and in vivo analyses of MEP pathway enzymes and aldolase. The ultimate goal
is for these assays to provide the sufficient throughput needed for kinetic and biomarker studies.
The specificity and sensitivity of HR-MS allows for reaction products to be conclusively used as
biomarkers for the inhibition of a particular enzyme. In the presence of inhibitors in vivo, this
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assay can be applied to quantitate the concentration of inhibitor present as well as confirm whether
the enzyme of interest is actually being targeted by the inhibitor. This information is vital to
determining whether an inhibitor is “drug-like” or not and predicting promiscuous binding effects
that could lead to off-target effects.
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Table A.1: Linearity raw data with errors
[FBP] Average
SD
%RSD
Normalized
Intensity
0.1
0.0130
0.0117 90.72
0.5
0.0321
0.0107 33.25
1
0.2001
0.0300 15.01
2
0.7180
0.0482 6.71
5
1.9590
0.1375 7.02
10
4.1245
0.0893 2.17
20
8.6284
0.7292 8.45
25
12.745
0.2571 2.02
50
24.174
0.8291 3.43
75
40.175
0.9280 2.31
100
55.252
1.9266 3.49
500
233.35
18.278 7.83

Table A.2: Raw data from 10 μM discontinuous reaction
Time (min) [FBP] (μM)
0
9.460
1
5.900
2
3.863
5
2.593
10
1.615
15
1.051
20
0.985
30
0.889
45
0.807
60
0.865
Quantitation based on RF 0.163
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No Inhibitor

Control (0 μM FBP)
0.3

[FBP] (μM)

0.25
0.2
0.15

y = -0.0153x + 0.2252
R² = 0.7536

0.1
0.05
0
0

1

2

3

4

5

6

Time (min)

2 μM
1.4
1.2

[FBP] (μM)

1
0.8
0.6
0.4
0.2
0
0

1

2

3

4

Time (min)

5

6

7

8
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2 μM Initial Rate
1.4
1.2

[FBP] (μM)

1
y = -0.6306x + 1.2895
R² = 0.9845

0.8
0.6
0.4
0.2
0
0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

Time (min)

5 μM
5
4.5
4

[FBP] (μM)

3.5
3
2.5
2
1.5
1
0.5
0
0

5

10

15

20

Time (min)

25

30

35
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5 μM Initial Rate
5
4.5
4

[FBP] (μM)

3.5
3
y = -1.3681x + 4.2556
R² = 0.9918

2.5
2
1.5
1
0.5
0
0

0.2

0.4

0.6

0.8

1

1.2

Time (min)

10 μM
10
9

[FBP] (μM)

8
7
6
5
4
3
2
1
0
0

10

20

30

40

Time (min)

50

60

70
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10 μM Initial Rate
10
9
8

[FBP] (μM)

7
6
5
y = -2.7985x + 9.2065
R² = 0.9759

4
3
2
1
0
0

0.5

1

1.5

2

2.5

Time (min)

15 μM
9
8

[FBP] (μM)

7
6
5
4
3
2
1
0
0

1

2

3

4

Time (min)

5

6

7

8
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15 μM Initial Rate
8.6
8.4

[FBP] (μM)

8.2
8
7.8
7.6

y = -3.4557x + 8.8029
R² = 0.9836

7.4
7.2
7
6.8
0

0.1

0.2

0.3

0.4

0.5

0.6

Time (min)

25 μM
20
18
16

[FBP] μM

14
12
10
8
6
4
2
0
0

10

20

30

40

Time (min)

50

60

70
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25 μM Initial Rate
25

[FBP] μM

20
15
10

y = -7.7429x + 19.199
R² = 0.8331

5
0
0

0.2

0.4

0.6

0.8

1

1.2

Time (min)

50 μM
50
45

[FBP] (μM)

40
35
30
25
20
15
10
5
0
0

0.5

1

1.5

Time (min)

2

2.5
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50 μM Initial Rate
45.5
45

[FBP] (μM)

44.5
44
43.5
43
42.5

y = -15.395x + 44.908
R² = 0.9645

42
41.5
41
40.5
0

0.05

0.1

0.15

0.2

0.25

0.3

4

5

6

Time (min)

1μM AMP

Control
0.25

[FBP] (μM)

0.2
0.15
y = 0.0046x + 0.1699
R² = 0.1045

0.1
0.05
0
0

1

2

3

Time (min)
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2 μM
2.5

[FBP] (μM)

2
1.5
1
0.5
0
0

1

2

3

4

5

6

7

8

1

1.2

1.4

1.6

Time (min)

2 μM Initial Rate
2.5

[FBP] (μM)

2
1.5
y = -0.2333x + 1.9707
R² = 0.4972

1
0.5
0
0

0.2

0.4

0.6

0.8

Time (min)
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5 μM
4.6

[FBP] (μM)

4.5
4.4
4.3
4.2
4.1
4
0

1

2

3

4

5

6

Time (min)

5 μM Initial Rate
4.6

[FBP] (μM)

4.5
4.4
4.3
y = -0.4807x + 5.0409
R² = 0.9991

4.2
4.1
4
0

0.5

1

1.5

Time (min)

2

2.5
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10 μM
9

[FBP] (μM)

8
7
6
5
4
3
0

1

2

3

4

5

6

0.8

1

1.2

Time (min)

10 μM Initial Rate
8.8
8.7

[FBP] (μM)

8.6
8.5
8.4
8.3
8.2

y = -0.8264x + 8.7489
R² = 0.9999

8.1
8
7.9
7.8
0

0.2

0.4

0.6

Time (min)
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15 μM
16
14

[FBP] (μM)

12
10
8
6
4
2
0
0

1

2

3

4

5

6

7

8

Time (min)

15 μM Initial Rate
14
13.8

[FBP] (μM)

13.6
13.4
13.2
13
y = -1.4509x + 13.863
R² = 0.8867

12.8
12.6
12.4
12.2
0

0.2

0.4

0.6

Time (min)

0.8

1

1.2
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25 μM
16
14

[FBP] (μM)

12
10
8
6
4
2
0
0

1

2

3

4

5

6

7

8

Time (min)

25 μM Initial Rate
14.4
14.2

[FBP] (μM)

14
13.8
13.6
13.4
y = -1.5522x + 14.305
R² = 0.9776

13.2
13
12.8
12.6
0

0.2

0.4

0.6

Time (min)

0.8

1

1.2
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50 μM Initial Rate
50
45

[FBP] (μM)

40
35
30
25

y = 4.3268x + 37.674
R² = 0.2955

20
15
10
5
0
0

0.2

0.4

0.6

0.8

Time (min)

1 μM ATP

1

1.2

1.4

1.6
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Control
0.18
0.16

[FBP] (μM)

0.14
0.12
0.1
0.08
y = -0.0236x + 0.1442
R² = 0.6408

0.06
0.04
0.02
0
0

0.5

1

1.5

2

2.5

Time (min)

2 μM
1.8
1.6

[FBP] (μM)

1.4
1.2
1
0.8
0.6
0.4
0.2
0
0

1

2

3

Time (min)

4

5

6
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2 μM Initial Rate
1.8
1.6

[FBP] (μM)

1.4
1.2
1
0.8

y = -0.0619x + 1.469
R² = 0.3623

0.6
0.4
0.2
0
0

1

2

3

4

5

6

4

5

6

Time (min)

5 μM
3.05
3

[FBP] (μM)

2.95
2.9
2.85
2.8
2.75
2.7
2.65
2.6
2.55
0

1

2

3

Time (min)
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5 μM Initial Rate
3.05
3

[FBP] (μM)

2.95
2.9
2.85
2.8
2.75

y = -0.1991x + 2.9966
R² = 0.9374

2.7
2.65
2.6
2.55
0

0.5

1

1.5

2

2.5

Time (min)

10 μM
5.85
5.8

[FBP] (μM)

5.75
5.7
5.65
5.6
5.55
5.5
0

1

2

3

Time (min)

4

5

6
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10 μM Initial Rate
7
6

[FBP] (μM)

5
4
y = -0.1802x + 5.8233
R² = 0.9831

3
2
1
0
0

0.2

0.4

0.6

0.8

1

1.2

Time (min)

15 μM Initial Rate
13.1
13

[FBP] (μM)

12.9
12.8
12.7
12.6
12.5

y = 0.4755x + 12.318
R² = 0.8219

12.4
12.3
12.2
0

0.2

0.4

0.6

0.8

Time (min)

1

1.2

1.4

1.6
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25 μM
21.8

[FBP] (μM)

21.6
21.4
21.2
21
20.8
20.6
0

0.5

1

1.5

2

2.5

3

3.5

0.7

0.8

Time (min)

25 μM Initial Rate
21.2

[FBP] (μM)

21.1
21
20.9
y = -0.4924x + 21.108
R² = 0.4559

20.8
20.7
20.6
0

0.1

0.2

0.3

0.4

Time (min)

0.5

0.6
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50 μM Initial Rate
46.2
46

[FBP] (μM)

45.8
45.6
y = 2.0853x + 44.867
R² = 0.8573

45.4
45.2
45
44.8
0

0.1

0.2

0.3

Time (min)

0.4

0.5

0.6

